Constructs for expressing transgenes using regulatory elements from Brachypodium ubiquitin 1C genes

CONSTRUCTS FOR EXPRESSING TRANSGENES USING REGULATORY ELEMENTS FROM BRACHYPODIUM UBIQUITIN 1C GENES

This application is a divisional of Australian patent application no. 2014312166 and claims priority from U.S. Provisional Patent Application No. 61/872,134, filed August 30, 2013, the entire contents of which are incorporated herein by reference.

Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 64 KB ACII (Text) file named “Brach_UBI_lC_SEQ_LIST_ST25” created on August 15, 2014.

Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and/or combined with other pieces of prior art by a skilled person in the art.

As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude other additives, components, integers or steps.

Plant transformation is an attractive technology for use in introducing agronomically desirable traits or characteristics into different crop plant species. Plant species are developed and/or modified to have particular desirable traits. Generally, desirable traits include, for example, improving nutritional value quality, increasing yield, conferring pest or disease resistance, increasing drought and stress tolerance, improving horticultural qualities (e.g., pigmentation and growth), imparting herbicide resistance, enabling the production of industrially useful compounds and/or materials from the plant, and/or enabling the production of pharmaceuticals.

Transgenic plants comprising multiple transgenes stacked at a single genomic locus are produced via plant transformation technologies. Plant transformation technologies result in the introduction of a transgene into a plant cell, recovery of a fertile transgenic plant that contains the stably integrated copy of the transgene in the plant genome, and subsequent transgene expression via transcription and translation of the transgene(s) results in transgenic plants that possess desirable traits and phenotypes. Each transgene in a stack typically requires an independent promoter for gene expression, and thus multiple promoters are used in a transgene stack.

The need for co-expression of multiple transgenes for regulating the same trait frequently results in the repeated use of the same promoter to drive expression of the multiple transgenes.

However, the repeated use of promoters comprising sequences that share a high level of sequence identity may lead to homology-based gene silencing (HBGS). HBGS has been observed to occur frequently in transgenic plants (Peremarti et ah, 2010) when repetitive DNA sequences are used within a transgene. In addition, repeated use of similar DNA sequences in transgene constructs has proven to be challenging in Agrobacterium due to recombination and instability of the plasmid.

Described herein are ubiquitin regulatory elements (e.g., promoters and 3’-UTR) that share low levels of sequence identity or homology with the Maize ubiquitin 1 promoter. Further described are constmcts and methods utilizing ubiquitin regulatory elements.

Disclosed herein are constructs and methods for expressing a transgene in plant cells and/or plant tissues. In one embodiment regulatory elements of a ubiquitin gene are purified from Panicum virgatum, Brachypodium distachyon, or Setaria italica genomes and recombined with sequences not natively linked to the regulatory elements to create an expression vector for expressing transgenes in plant cells not native to the ubiquitin regulatory sequences. In one embodiment an expression vector is provided wherein the regulatory elements of a ubiquitin gene are operably linked to a polylinker sequence. Such an expression vector eases the insertion of a gene or gene cassette into the vector in an operably linked state with the ubiquitin gene regulatory sequences.

In an embodiment, a construct is provided comprising a Panicum virgatum, Brachypodium distachyon, or Setaria italica ubiquitin promoter. In an embodiment, a gene expression cassette is provided comprising a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter operably linked to a transgene. In an embodiment, a gene expression cassette includes a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 5’ -UTR operably linked to a transgene. In an embodiment, a gene expression cassette includes a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 5’ -UTR operably linked to a promoter. In an embodiment, a gene expression cassette includes a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin intron operably linked to a transgene. In an embodiment, a gene expression cassette includes a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin intron operably linked to a promoter. In an embodiment, a construct includes a gene expression cassette comprising Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 3’-UTR. In an embodiment, a gene expression cassette includes Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 3’-UTR operably linked to a transgene. In an embodiment, a gene expression cassette includes at least one, two, three, five, six, seven, eight, nine, ten, or more_transgenes.

In an embodiment, a gene expression cassette includes independently a) a Panicum virgatum, Brachypodium distachyon, or Setaria italica ubiquitin promoter, b) a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin intron, c) a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 5’-UTR, and d) a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 3"-UTR.

In accordance with one embodiment a nucleic acid vector is provided comprising a promoter operably linked to a non-ubiquitin transgene, wherein the promoter consists of SEQ ID NO: 15 or a sequence having 90% sequence identity with SEQ ID NO: 15. In a further embodiment the nucleic acid vector comprises a gene cassette, wherein the gene cassette comprises a promoter, a non-ubiquitin transgene and a 3' untranslated region, wherein the promoter consists of SEQ ID NO: 15 operably linked to a first end of a transgene, wherein the second end of the transgene is operably linked to a 3’ untranslated sequence consisting of SEQ ID NO: 4.

Methods of growing plants expressing a transgene using the Panicum virgatum, Brachypodium distachyon, or Setaria italica promoters, 5’ -UTRs, introns, and 3’-UTRs are disclosed herein. Methods of culturing plant tissues and cells expressing a transgene using the Panicum virgatum, Brachypodium distachyon or Setaria italica promoters, 5’ -UTRs, introns, and 3’-UTRs are also disclosed herein.

In accordance with one embodiment a plant, plant tissue, or plant cell is provided comprising a promoter operably linked to a non-ubiquitin transgene, wherein the promoter comprises SEQ ID NO: 1. In accordance with one embodiment a non-Brachypodium plant or plant cell is provided comprising SEQ ID NO: 1, or a sequence that has 90% sequence identity with SEQ ID NO: 1 operably linked to a transgene. In one embodiment the plant is a com variety. In one embodiment a plant, plant tissue, or plant cell is provided comprising a promoter operably linked to a non-ubiquitin transgene, wherein the promoter consists of SEQ ID NO: 15 or 40. In one embodiment a non-Brachypodium plant or plant cell is provided comprising a gene cassette, wherein the gene cassette comprises a promoter operably linked to a transgene, further wherein the promoter consists SEQ ID NO: 15. In a further embodiment the promoter is operably linked to a first end of a transgene, wherein the second end of the transgene is operably linked to a 3' untranslated sequence consisting of SEQ ID NO: 4.

FIG. 1 shows the protein alignment of Ζ℮α mays ubiquitin (ΖΜ Ubil) protein sequence to Brachypodium distachyon and Setaria italic ubiquitin sequences used for promoter identification. The Zm Ubil protein sequence is disclosed herein as SEQ ID Ν0:22. The S. italica Ubi2 protein sequence is disclosed herein as SEQ ID ΝΟ:23. The Β. distachyon Ubil promoter sequence is disclosed herein as SEQ ID ΝΟ:24. The Β. distachyon Ubi 1C protein sequence is disclosed herein as SEQ ID ΝΟ:25. The consensus sequence is disclosed herein as SEQ ID ΝΟ:26.

FIG. 2 shows the alignment of Zea mays ubiquitin (ΖΜ Ubil) promoter polynucleotide sequence to Brachypodium distachyon and Setaria italica ubiquitin promoter polynucleotides identified herein. The Zea may Ubiquitin 1 (Zm-Ubi) promoter sequence is disclosed herein as SEQ ID ΝΟ:27. The Β. distachyon Ubil promoter sequence is disclosed herein as SEQ ID NO: 16. The Β. distachyon Ubil-C promoter sequence is disclosed herein as SEQ ID NO: 15. The S. italica Ubi2 promoter sequence is disclosed herein as SEQ ID NO: 17.

FIG. 3 is a plasmid map showing the synthesized Setaria italica Ubiquitin2 promoter genetic element.

FIG. 4 is plasmid map showing the synthesized Brachypodium distachyon Ubiquitin 1 C promoter genetic element and flanking seamless cloning overhang location.

FIG. 5 is plasmid map showing the synthesized Brachypodium distachyon Ubiquitin 1 promoter genetic element and flanking seamless cloning overhang location.

FIG. 6 is plasmid map showing the expression vector containing Setaria italica ubiquitin2 (SI-Ubi2) promoter fused to PhiYFP reporter gene.

FIG. 7 is plasmid map showing the expression vector containing Brachypodium distachyon Ubiquitinl C promoter fused to PhiYFP reporter gene.

FIG. 8 is a plasmid map showing the expression vector containing Brachypodium distachyon Ubiquitinl promoter fused to PhiYFP reporter gene.

FIG. 9 is a plasmid map showing the expression vector containing OS Actl (Rice Actinl) promoter fused to PhiYFP reporter gene.

FIG. 10 is a plasmid map showing the expression vector containing ΖΜ Ubi 1 promoter fused to PhiYFP reporter gene.

FIG. 11 is a plasmid map showing the binary destination vector used to build binary expression vectors using Gateway technology.

FIG. 12 is a plasmid map showing the binary expression vector containing Setaria italica Ubiquitin2 (SI-Ubi2) promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a StPinll 3'UTR from potato.

FIG. 13 is a plasmid map showing the binary expression vector containing Brachypodium distachyon Ubiquitinl C promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a StPinll 3'UTR from potato.

FIG. 14 is a plasmid map showing the binary expression vector containing Brachypodium distachyon Ubiquitinl promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a StPinll 3'UTR from potato.

FIG. 15 is a plasmid map showing the binary expression vector containing OS Actl promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a StPinll 3'UTR from potato.

FIG. 16 is a plasmid map showing the binary expression vector containing ZM Ubil promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LSI intron followed by fragment comprising a StPinll 3'UTR from potato.

FIG. 17 shows YFP expression in a To leaf where YFP is driven by the cross species ubiquitin and Os Act 1 promoters as depicted in Figures 12, 13, 14, 15, and 16.

FIG. 18 shows AAD1 expression in a T₀ leaf where AAD1 is driven by the Zm Ubi 1 promoter as depicted in Figures 12, 13, 14, 15, and 16.

FIG. 19 shows transient YFP expression driven by the Brachypodium distachyon and Setaria italica novel promoters as compared to YFP expression driven by the ZM Ubil and OS Actl promoters.

FIG. 20 shows YFP expression in calli tissues driven by the novel Brachypodium distachyon and Setaria italica promoters as compared to YFP expression driven by the ZM Ubil and OS Actl promoters.

FIG. 21 shows YFP expression in root tissue driven by the novel Brachypodium distachyon and Setaria italica promoters as compared to YFP expression driven by the ZM Ubil and OS Actl promoters.

FIG. 22 is a plasmid map showing the synthesized Panicum virgatum Ubiquitinl promoter genetic element and flanking seamless cloning overhang location.

FIG. 23 is plasmid map showing the synthesized Panicum virgatum Ubiquitinl 3’UTR genetic element and flanking seamless cloning overhang location.

FIG. 24 is plasmid map showing the synthesized Brachypodium distachyon UbiquitinlC 3’UTR genetic element and flanking seamless cloning overhang location.

FIG. 25 is plasmid map showing the synthesized Brachypodium distachyon Ubiquitinl 3’UTR genetic element and flanking seamless cloning overhang location.

FIG. 26 is plasmid map showing the synthesized Setaria italica ubiquitin2 (SI-Ubi2) 3’UTR genetic element and flanking seamless cloning overhang location.

FIG. 27 is plasmid map showing the expression vector containing Panicum virgatum Ubiquitin 1 promoter and 3’UTR fused to PhiYFP reporter gene.

FIG. 28 is plasmid map showing the expression vector containing Brachypodium distachyon Ubiquitin 1 C promoter and 3’UTR fused to PhiYFP reporter gene.

FIG. 29 is a plasmid map showing the expression vector containing Setaria italica ubiquitin2 promoter and 3’UTR fused to PhiYFP reporter gene.

FIG. 30 is plasmid map showing the expression vector containing Brachypodium distachyon Ubiquitin 1 promoter and 3’UTR fused to PhiYFP reporter gene.

FIG. 31 is a plasmid map showing the binary expression vector containing Brachypodium distachyon Ubiquitin 1 C promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a Brachypodium distachyon Ubiquitinl C 3’UTR.

FIG. 32 is a plasmid map showing the binary expression vector containing Panicum virgatum Ubiquitinl promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a Panicum virgatum Ubiquitinl 3’UTR.

FIG. 33 is a plasmid map showing the binary expression vector containing Setaria italica ubiquitin2 promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a Setaria italica ubiquitin2 3’UTR.

FIG. 34 is a plasmid map showing the binary expression vector containing Brachypodium distachyon Ubiquitinl promoter fused to yellow fluorescent protein (Phi YFP) marker gene coding region containing ST-LS1 intron followed by fragment comprising a Brachypodium distachyon Ubiquitinl 3’UTR.

FIG. 35 presents the Brachypodium distachyon Ubiquitinl C coding sequence and putative promoter (upstream sequence of ATG). The upstream promoter sequence is underlined, the 5’-UTR sequence is presented in uppercase, the intron is boxed, the Ubil CDS is in italics, the 3’-UTR (underlined) and the transcription termination sequence is downstream of ΤΑΑ (Translational Stop Codon).

FIG. 36 presents the Brachypodium distachyon Ubiquitin 1 coding sequence and putative promoter. The upstream promoter is underlined, the 5’UTR sequence is in uppercase, the intron is boxed, the CDS is in italics, the 3’-UTR (underlined) and transcription termination sequence is downstream of ΤΑΑ (Translational Stop Codon).

FIG. 37 presents the Setaria italica Ubiquitin2 coding sequence and putative promoter.

The upstream promoter is underlined, the 5’UTR sequence is in uppercase, the intron is boxed, the CDS is in italics, the 3’-UTR (underlined) and transcription termination sequence is downstream of ΤΑΑ (Translational Stop Codon).

FIG. 38 presents the Panicum virgatum (Switchgrass ) Ubiquitin 1 coding sequence and putative promoter. The upstream promoter is underlined, the 5’UTR sequence is in uppercase, the intron is boxed, the CDS is in italics, the 3’-UTR (underlined) and transcription termination sequence is downstream of ΤΑΑ (Translational Stop Codon).

DETAILED DESCRIPTION

In describing and claiming the invention, the following terminology will be used in accordance with the definitions set forth below.

The term "about" as used herein means greater or lesser than the value or range of values stated by 10 percent, but is not intended to designate any value or range of values to only this broader definition. Each value or range of values preceded by the term "about" is also intended to encompass the embodiment of the stated absolute value or range of values.

As used herein, the term” backcrossing” refers to a process in which a breeder crosses hybrid progeny back to one of the parents, for example, a first generation hybrid FI with one of the parental genotypes of the FI hybrid.

A "promoter" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. A promoter may contain specific sequences that are recognized by transcription factors. These factors may bind to a promoter DNA sequence, which results in the recruitment of RNA polymerase. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease SI), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. The promoter may be operatively associated with other expression control sequences, including enhancer and repressor sequences.

For the puiposes of the present disclosure, a "gene," includes a DNA region encoding a gene product (see infra), as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.

As used herein the terms "native" or "natural" define a condition found in nature. A "native DNA sequence" is a DNA sequence present in nature that was produced by natural means or traditional breeding techniques but not generated by genetic engineering (e.g., using molecular biology/transformation techniques).

As used herein a "transgene" is defined to be a nucleic acid sequence that encodes a gene product, including for example, but not limited to, an mRNA. In one embodiment the transgene is an exogenous nucleic acid, where the transgene sequence has been introduced into a host cell by genetic engineering (or the progeny thereof) where the transgene is not normally found. In one example, a transgene encodes an industrially or pharmaceutically useful compound, or a gene encoding a desirable agricultural trait (e.g., an herbicide-resistance gene). In yet another example, a transgene is an antisense nucleic acid sequence, wherein expression of the antisense nucleic acid sequence inhibits expression of a target nucleic acid sequence. In one embodiment the transgene is an endogenous nucleic acid, wherein additional genomic copies of the endogenous nucleic acid are desired, or a nucleic acid that is in the antisense orientation with respect to the sequence of a target nucleic acid in a host organism.

As used herein the term "non-ubiquitin transgene" is any transgene that has less than 80% sequence identity with the Zea may Ubiquitin 1 coding sequence (SEQ ID ΝΟ:27).

"Gene expression" as defined herein is the conversion of the information, contained in a gene, into a gene product.

A "gene product" as defined herein is any product produced by the gene. For example the gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, interfering RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of a mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation. Gene expression can be influenced by external signals, for example, exposure of a cell, tissue, or organism to an agent that increases or decreases gene expression. Expression of a gene can also be regulated anywhere in the pathway from DNA to RNA to protein. Regulation of gene expression occurs, for example, through controls acting on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization, or degradation of specific protein molecules after they have been made, or by combinations thereof. Gene expression can be measured at the RNA level or the protein level by any method known in the art, including, without limitation, Northern blot, RT-PCR, Western blot, or in vitro, in situ, or in vivo protein activity assay(s).

As used herein, the term “intron” is defined as any nucleic acid sequence comprised in a gene (or expressed nucleotide sequence of interest) that is transcribed but not translated. Introns include untranslated nucleic acid sequence within an expressed sequence of DNA, as well as corresponding sequence in RNA molecules transcribed therefrom. A construct described herein can also contain sequences that enhance translation and/or mRNA stability such as introns. An example of one such intron is the first intron of gene II of the histone Η3 variant of Arabidopsis thaliana or any other commonly known intron sequence. Introns can be used in combination with a promoter sequence to enhance translation and/or mRNA stability.

As used herein, the terms “5’ untranslated region” or “5’-UTR” is defined as the untranslated segment in the 5’ terminus of pre-mRNAs or mature mRNAs. For example, on mature mRNAs, a 5’-UTR typically harbors on its 5’ end a 7-methylguanosine cap and is involved in many processes such as splicing, polyadenylation, mRNA export towards the cytoplasm, identification of the 5’ end of the mRNA by the translational machinery, and protection of the mRNAs against degradation.

As used herein, the terms “transcription terminator” is defined as the transcribed segment in the 3’ terminus of pre-mRNAs or mature mRNAs. For example, longer stretches of DNA beyond “polyadenylation signal” site is transcribed as a pre-mRNA. This DNA sequence usually contains one or more transcription termination signals for the proper processing of the pre-mRNA into mature mRNA.

As used herein, the term “3’ untranslated region” or “3’-UTR” is defined as the untranslated segment in a 3’ terminus of the pre-mRNAs or mature mRNAs. For example, on mature mRNAs this region harbors the poly-(A) tail and is known to have many roles in mRNA stability, translation initiation, and mRNA export.

As used herein, the term “polyadenylation signal” designates a nucleic acid sequence present in mRNA transcripts that allows for transcripts, when in the presence of a poly-(A) polymerase, to be polyadenylated on the polyadenylation site, for example, located 10 to 30 bases downstream of the poly-(A) signal. Many polyadenylation signals are known in the art and are useful for the present invention. An exemplary sequence includes AAUAAA and variants thereof, as described in Loke J., et al., (2005) Plant Physiology 138(3); 1457-1468.

The term “isolated” as used herein means having been removed from its natural environment, or removed from other compounds present when the compound is first formed.

The term “isolated” embraces materials isolated from natural sources as well as materials (e.g., nucleic acids and proteins) recovered after preparation by recombinant expression in a host cell, or chemically-synthesized compounds such as nucleic acid molecules, proteins, and peptides.

The term “purified,” as used herein relates to the isolation of a molecule or compound in a foim that is substantially free of contaminants normally associated with the molecule or compound in a native or natural environment, or substantially enriched in concentration relative to other compounds present when the compound is first formed, and means having been increased in purity as a result of being separated from other components of the original composition. The term "purified nucleic acid" is used herein to describe a nucleic acid sequence which has been separated, produced apart from, or purified away from other biological compounds including, but not limited to polypeptides, lipids and carbohydrates, while effecting a chemical or functional change in the component (e.g.₇ a nucleic acid may be purified from a chromosome by removing protein contaminants and breaking chemical bonds connecting the nucleic acid to the remaining DNA in the chromosome).

As used herein, the terms “homology-based gene silencing” or “HBGS” are generic teims that include both transcriptional gene silencing and posttranscriptional gene silencing. Silencing of a target locus by an unlinked silencing locus can result from transcription inhibition (transcriptional gene silencing; TGS) or mRNA degradation (post-transcriptional gene silencing;

PTGS), owing to the production of double-stranded RNA (dsRNA) corresponding to promoter or transcribed sequences, respectively. Involvement of distinct cellular components in each process suggests that dsRNA-induced TGS and PTGS likely result from the diversification of an ancient common mechanism. However, a strict comparison of TGS and PTGS has been difficult to achieve because it generally relies on the analysis of distinct silencing loci. A single transgene locus can be described to trigger both TGS and PTGS, owing to the production of dsRNA corresponding to promoter and transcribed sequences of different target genes.

As used herein, the terms “nucleic acid molecule”, “nucleic acid”, or “polynucleotide” (all three terms are synonymous with one another) refer to a polymeric form of nucleotides, which may include both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms, and mixed polymers thereof. "A nucleotide" may refer to a ribonucleotide, deoxyribonucleotide, or a modified form of either type of nucleotide. A nucleic acid molecule is usually at least 10 bases in length, unless otherwise specified. The terms may refer to a molecule of RN A or DNA of indeterminate length. The teims include single- and double-stranded forms of DNA. A nucleic acid molecule may include either or both naturally-occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages.

Nucleic acid molecules may be modified chemically or biochemically, or may contain nonnatural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art.

Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, intemucleotide modifications (e.g., uncharged linkages: for example, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.; charged linkages: for example, phosphorothioates, phosphorodithioates, etc.; pendent moieties: for example, peptides; intercalators: for example, acridine, psoralen, etc.; chelators;

alkylators; and modified linkages: for example, alpha anomeric nucleic acids, etc.). The term “nucleic acid molecule” also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular, and padlocked conformations.

Transcription proceeds in a 5’ to 3’ manner along a DNA strand. This means that RNA is made by sequential addition of ribonucleotide-5'-triphosphates to the 3’ terminus of the growing chain (with a requisite elimination of the pyrophosphate). In either a linear or circular nucleic acid molecule, discrete elements {e.g., particular nucleotide sequences) may be referred to as being “upstream” relative to a further element if they are bonded or would be bonded to the same nucleic acid in the 5’ direction from that element. Similarly, discrete elements may be “downstream” relative to a further element if they are or would be bonded to the same nucleic acid in the 3’ direction from that element.

As used herein, the term “base position,” refers to the location of a given base or nucleotide residue within a designated nucleic acid. A designated nucleic acid may be defined by alignment with a reference nucleic acid.

As used herein, the term “hybridization” refers to a process where oligonucleotides and them analogs hybridize by hydrogen bonding, which includes Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary bases. Generally, nucleic acid molecules consist of nitrogenous bases that are either pyrimidines (cytosine (C), uracil (U), and thymine (Τ)) or purines (adenine (A) and guanine (G)). These nitrogenous bases form hydrogen bonds between a pyrimidine and a purine, and bonding of a pyrimidine to a purine is referred to as “base pairing.” More specifically, A will hydrogen bond to Τ or U, and G will bond to C.

“Complementary” refers to the base pairing that occurs between two distinct nucleic acid sequences or two distinct regions of the same nucleic acid sequence.

As used herein, the terms “specifically hybridizable” and “specifically complementary’ refers to a sufficient degree of complementarity such that stable and specific binding occurs between an oligonucleotide and the DNA or RNA target. Oligonucleotides need not be 100% complementary to its target sequence to specifically hybridize. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA, and there is sufficient degree of complementarity to avoid non-specific binding of an oligonucleotide to non-target sequences under conditions where specific binding is desired, for example under physiological conditions in the case of in vivo assays or systems. Such binding is referred to as specific hybridization.

Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the chosen hybridization method and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (especially Na⁺ and/or Mg²⁺ concentration) of a hybridization buffer will contribute to the stringency of hybridization, though wash times also influence stringency. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed in Sambrook el αℓ. (ed.), Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, chs. 9 and 11.

As used herein, the term “stringent conditions” encompasses conditions under which hybridization will only occur if there is less than 50% mismatch between the hybridization molecule and the DNA target. “Stringent conditions” include further particular levels of stringency. Thus, as used herein, “moderate stringency” conditions are those under which molecules with more than 50% sequence mismatch will not hybridize; conditions of “high stringency” are those under which sequences with more than 20% mismatch will not hybridize;

and conditions of “very high stringency” are those under which sequences with more than 10% mismatch will not hybridize. In particular embodiments, stringent conditions can include hybridization at 65°C, followed by washes at 65°C with 0.1χ SSC/0.1% SDS for 40 minutes. The following are representative, non-limiting hybridization conditions:

• Very High Stringency: hybridization in 5χ SSC buffer at 65°C. for 16 hours;

wash twice in 2χ SSC buffer at room temperature for 15 minutes each; and wash twice in 0.5χ SSC buffer at 65°C for 20 minutes each.

• High Stringency: Hybridization in 5-6 χ SSC buffer at 65-70°C for 16-20

hours; wash twice in 2 χ SSC buffer at room temperature for 5-20 minutes each; and wash twice in lx SSC buffer at 55-70°C for 30 minutes each.

• Moderate Stringency: Hybridization in 6χ SSC buffer at room temperature to 55°C for 16-20 hours; wash at least twice in 2χ-3χ SSC buffer at room temperature to 55°C for 20-30 minutes each.

In an embodiment, specifically hybridizable nucleic acid molecules can remain bound under very high stringency hybridization conditions. In an embodiment, specifically hybridizable nucleic acid molecules can remain bound under high stringency hybridization conditions. In an embodiment, specifically hybridizable nucleic acid molecules can remain bound under moderate stringency hybridization conditions.

As used herein, the term “oligonucleotide” refers to a short nucleic acid polymer.

Oligonucleotides may be formed by cleavage of longer nucleic acid segments, or by polymerizing individual nucleotide precursors. Automated synthesizers allow the synthesis of oligonucleotides up to several hundred base pairs in length. Because oligonucleotides may bind to a complementary nucleotide sequence, they may be used as probes for detecting DNA or RNA.

Oligonucleotides composed of DNA (oligodeoxyribonucleotides) may be used in PCR, a technique for the amplification of small DNA sequences. In PCR, an oligonucleotide is typically referred to as a “primer,” which allows a DNA polymerase to extend the oligonucleotide and replicate the complementary strand.

As used herein, the terms “Polymerase chain reaction” or “PCR” define a procedure or technique in which minute amounts of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Pat. No. 4,683,195 issued July 28, 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5’ terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et αℓ., Cold Spring Harbor Symp. Quant. Biol., 51:263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989).

As used herein, the term “primer” refers to an oligonucleotide capable of acting as a point of initiation of synthesis along a complementary strand when conditions are suitable for synthesis of a primer extension product. The synthesizing conditions include the presence of four different deoxyribonucleotide triphosphates and at least one polymerization-inducing agent such as reverse transcriptase or DNA polymerase. These are present in a suitable buffer, which may include constituents which are co-factors or which affect conditions such as pH and the like at various suitable temperatures. A primer is preferably a single strand sequence, such that amplification efficiency is optimized, but double stranded sequences can be utilized.

As used herein, the term “probe” refers to an oligonucleotide that hybridizes to a target sequence. In the TaqMan® or TaqMan®-style assay procedure, the probe hybridizes to a portion of the target situated between the annealing site of the two primers. A probe includes about eight nucleotides, about ten nucleotides, about fifteen nucleotides, about twenty nucleotides, about thirty nucleotides, about forty nucleotides, or about fifty nucleotides. In some embodiments, a probe includes from about eight nucleotides to about fifteen nucleotides.

A probe can further include a detectable label, e.g., a fluorophore (Texas-Red®, Fluorescein isothiocyanate, etc.,). The detectable label can be covalently attached directly to the probe oligonucleotide, e.g., located at the probe’s 5’ end or at the probe’s 3’ end. A probe including a fluorophore may also further include a quencher, e.g., Black Hole Quencher™, Iowa Black™, etc.

As used herein, the terms “sequence identity” or “identity” can be used interchangeably and refer to nucleic acid residues in two sequences that are the same when aligned for maximum correspondence over a specified comparison window.

As used herein, the term “percentage of sequence identity” refers to a value determined by comparing two optimally aligned sequences (e.g., nucleic acid sequences or amino acid sequences) over a comparison window, wherein the portion of a sequence in the comparison window may comprise additions or deletions (ℓ℮., gaps) as compared to a reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. A percentage is calculated by determining the number of positions at which an identical nucleic acid or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to yield the percentage of sequence identity. Methods for aligning sequences for comparison are well known. Various programs and alignment algorithms are described in, for example: Smith and Waterman (1981) Adv. Αρρℓ. Math. 2:482; Needleman and Wunsch (1970) J. Mol. Biol. 48:443; Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U.S.A. 85:2444; Higgins and Sharp (1988) Gene 73:237-44; Higgins and Sharp (1989) CABIOS 5:151-3; Coipet et αℓ. (1988) Nucleic Acids Res. 16:10881-90; Huang et αℓ. (1992) Comp. Αρρℓ, Biosci. 8:155-65; Pearson et αℓ. (1994) Methods Mol. Biol. 24:307-31; Tatiana etal. (1999) FEMS Microbiol. Lett. 174:247-50.

The National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST™; Altschul et αℓ. (1990)./. Mol. Biol. 215:403-10) is available from several sources, including the National Center for Biotechnology Information (Bethesda, MD), and on the internet, for use in connection with several sequence analysis programs. A description of how to determine sequence identity using this program is available on the internet under the “help” section for BLAST™. For comparisons of nucleic acid sequences, the “Blast 2 sequences” function of the BLAST™ (Blastn) program may be employed using the default parameters. Nucleic acid sequences with even greater similarity to the reference sequences will show increasing percentage identity when assessed by this method.

As used herein, the term “operably linked” refers to two components that have been placed into a functional relationship with one another. The term, "operably linked," when used in reference to a regulatory sequence and a coding sequence, means that the regulatory sequence affects the expression of the linked coding sequence. "Regulatory sequences," “regulatory elements”, or "control elements," refer to nucleic acid sequences that influence the timing and level/amount of transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters; translation leader sequences; 5' and 3' untranslated regions, introns; enhancers; stem-loop structures; repressor binding sequences; termination sequences; polyadenylation recognition sequences; etc.

Particular regulatory sequences may be located upstream and/or downstream of a coding sequence operably linked thereto. Also, particular regulatory sequences operably linked to a coding sequence may be located on the associated complementary strand of a double-stranded nucleic acid molecule. Linking can be accomplished by ligation at convenient restriction sites.

If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. However, elements need not be contiguous to be operably linked.

As used herein, the term “transformation” encompasses all techniques by which a nucleic acid molecule can be introduced into such a cell. Examples include, but are not limited to:

transfection with viral vectors; transformation with plasmid vectors; electroporation; lipofection;

microinjection (Mueller etal. (1978) Cell 15:579-85); Agrobacterium-mediated transfer; direct DNA uptake; whiskers-mediated transformation; and microprojectile bombardment.

As used herein, the term “transduce” refers to a process where a virus transfers nucleic acid into a cell.

The terms "polylinker" or "multiple cloning site" as used herein defines a cluster of three or more Type -2 restriction enzyme sites located within 10 nucleotides of one another on a nucleic acid sequence. Constructs comprising a polylinker are utilized for the insertion and/or excision of nucleic acid sequences such as the coding region of a gene.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence. Type -2 restriction enzymes recognize and cleave DNA at the same site, and include but are not limited to Xbal, BamHI, Hindlll, EcoRI, Xhol, Sail, Kpnl, Aval, PstI and SmaL

The term "vector" is used interchangeably with the terms "construct", "cloning vector" and "expression vector" and means the vehicle by which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g.

transcription and translation) of the introduced sequence. A "non-viral vector" is intended to mean any vector that does not comprise a vims or retrovirus. In some embodiments a "vector " is a sequence of DNA comprising at least one origin of DNA replication and at least one selectable marker gene. Examples include, but are not limited to, a plasmid, cosmid, bacteriophage, bacterial artificial chromosome (BAC), or vims that carries exogenous DNA into a cell. A vector can also include one or more genes, antisense molecules, and/or selectable marker genes and other genetic elements known in the art. A vector may transduce, transform, or infect a cell, thereby causing the cell to express the nucleic acid molecules and/or proteins encoded by the vector.

The teim "plasmid" defines a circular strand of nucleic acid capable of autosomal replication in either a prokaryotic or a eukaiyotic host cell. The teim includes nucleic acid which may be either DNA or RNA and may be single- or double-stranded. The plasmid of the definition may also include the sequences which correspond to a bacterial origin of replication.

The teim "selectable marker gene" as used herein defines a gene or other expression cassette which encodes a protein which facilitates identification of cells into which the selectable marker gene is inserted. For example a “selectable marker gene” encompasses reporter genes as well as genes used in plant transformation to, for example, protect plant cells from a selective agent or provide resistance/tolerance to a selective agent. In one embodiment only those cells or plants that receive a functional selectable marker are capable of dividing or growing under conditions having a selective agent. Examples of selective agents can include, for example, antibiotics, including spectinomycin, neomycin, kanamycin, paromomycin, gentamicin, and hygromycin. These selectable markers include neomycin phosphotransferase (npt II), which expresses an enzyme conferring resistance to the antibiotic kanamycin, and genes for the related antibiotics neomycin, paromomycin, gentamicin, and G418, or the gene for hygromycin phosphotransferase (hpt), which expresses an enzyme confening resistance to hygromycin. Other selectable marker genes can include genes encoding herbicide resistance including bar or pat (resistance against glufosinate ammonium or phosphinothricin), acetolactate synthase (ALS, resistance against inhibitors such as sulfonylureas (SUs), imidazolinones (IMIs), triazolopyiimidines (TPs), pyrimidinyl oxybenzoates (POBs), and sulfonylamino carbonyl triazolinones that prevent the first step in the synthesis of the branched-chain amino acids), glyphosate, 2,4-D, and metal resistance or sensitivity. Examples of “reporter genes” that can be used as a selectable marker gene include the visual observation of expressed reporter gene proteins such as proteins encoding p-glucuronidase (GUS), luciferase, green fluorescent protein (GFP), yellow fluorescent protein (YFP), DsRed, (l-galactosidasc. chloramphenicol acetyltransferase (CAT), alkaline phosphatase, and the like. The phrase “marker-positive” refers to plants that have been transformed to include a selectable marker gene.

As used herein, the term “detectable marker” refers to a label capable of detection, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator, or enzyme. Examples of detectable markers include, but are not limited to, the following: fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, (l-galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In an embodiment, a detectable marker can be attached by spacer arms of various lengths to reduce potential steric hindrance.

As used herein, the term “detecting” is used in the broadest sense to include both qualitative and quantitative measurements of a specific molecule, for example, measurements of a specific polypeptide.

As used herein, the terms "cassette", "expression cassette" and "gene expression cassette" refer to a segment of DNA that can be inserted into a nucleic acid or polynucleotide at specific restriction sites or by homologous recombination. As used herein the segment of DNA comprises a polynucleotide that encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation. In an embodiment, an expression cassette can include a polynucleotide that encodes a polypeptide of interest and having elements in addition to the polynucleotide that facilitate transformation of a particular host cell. In an embodiment, a gene expression cassette may also include elements that allow for enhanced expression of a polynucleotide encoding a polypeptide of interest in a host cell. These elements may include, but are not limited to: a promoter, a minimal promoter, an enhancer, a response element, a terminator sequence, a polyadenylation sequence, and the like.

As used herein a "linker" or "spacer" is a bond, molecule or group of molecules that binds two separate entities to one another. Linkers and spacers may provide for optimal spacing of the two entities or may further supply a labile linkage that allows the two entities to be separated from each other. Labile linkages include photocleavable groups, acid-labile moieties, base-labile moieties and enzyme-cleavable groups.

As used herein, the term “control” refers to a sample used in an analytical procedure for comparison purposes. A control can be “positive” or “negative”. For example, where the purpose of an analytical procedure is to detect a differentially expressed transcript or polypeptide in cells or tissue, it is generally preferable to include a positive control, such as a sample from a known plant exhibiting the desired expression, and a negative control, such as a sample from a known plant lacking the desired expression.

As used herein, the term “plant” includes a whole plant and any descendant, cell, tissue, or part of a plant. A class of plant that can be used in the present invention is generally as broad as the class of higher and lower plants amenable to mutagenesis including angiosperms (monocotyledonous and dicotyledonous plants), gymnosperms, ferns and multicellular algae.

Thus, “plant” includes dicot and monocot plants. The term “plant parts” include any part(s) of a plant, including, for example and without limitation: seed (including mature seed and immature seed); a plant cutting; a plant cell; a plant cell culture; a plant organ (e.g., pollen, embryos, flowers, fruits, shoots, leaves, roots, stems, and explants). A plant tissue or plant organ may be a seed, protoplast, callus, or any other group of plant cells that is organized into a structural or functional unit. A plant cell or tissue culture may be capable of regenerating a plant having the physiological and morphological characteristics of the plant from which the cell or tissue was obtained, and of regenerating a plant having substantially the same genotype as the plant. In contrast, some plant cells are not capable of being regenerated to produce plants. Regenerable cells in a plant cell or tissue culture may be embryos, protoplasts, meristematic cells, callus, pollen, leaves, anthers, roots, root tips, silk, flowers, kernels, ears, cobs, husks, or stalks.

Plant parts include harvestable parts and parts useful for propagation of progeny plants.

Plant parts useful for propagation include, for example and without limitation: seed; fruit; a cutting; a seedling; a tuber; and a rootstock. A harvestable part of a plant may be any useful part of a plant, including, for example and without limitation: flower; pollen; seedling; tuber;

leaf; stem; fruit; seed; and root.

A plant cell is the structural and physiological unit of the plant, comprising a protoplast and a cell wall. A plant cell may be in the form of an isolated single cell, or an aggregate of cells (e.g., a friable callus and a cultured cell), and may be part of a higher organized unit (e.g., a plant tissue, plant organ, and plant). Thus, a plant cell may be a protoplast, a gamete producing cell, or a cell or collection of cells that can regenerate into a whole plant. As such, a seed, which comprises multiple plant cells and is capable of regenerating into a whole plant, is considered a “plant cell” in embodiments herein.

The term "protoplast," as used herein, refers to a plant cell that had its cell wall completely or partially removed, with the lipid bilayer membrane thereof naked, and thus includes protoplasts, which have their cell wall entirely removed, and spheroplasts, which have their cell wall only partially removed, but is not limited thereto. Typically, a protoplast is an isolated plant cell without cell walls which has the potency for regeneration into cell culture or a whole plant.

Unless otherwise specifically explained, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this disclosure belongs. Definitions of common terms in molecular biology can be found in, for example: Lewin, Genes V, Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et αℓ. (eds.), The Encyclopedia of Molecular Biology, Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Meyers (ed.), Molecular Biology and Biotechnology: A Comprehensive Desk Reference, VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

As disclosed herein novel recombinant constructs are provided for expressing a ηοηubiquitin transgene using the regulatory sequences of a ubiquitin gene from Panicum virgatum, Brachypodium distachyon, or Setaria italica. These constructs can be used to transform cells, including plant cells, to produce complete organisms that express the transgene gene product in their cells.

Plant promoters used for basic research or biotechnological application are generally unidirectional, directing only one gene that has been fused at its 3’ end (downstream). It is often necessary to introduce multiple genes into plants for metabolic engineering and trait stacking and therefore, multiple promoters are typically required in transgenic crops to drive the expression of multiple genes.

Development of transgenic products is becoming increasingly complex, which requires stacking multiple transgenes into a single locus. Traditionally, each transgene usually requires a promoter for expression wherein multiple promoters are required to express different transgenes within one gene stack. This frequently leads to repetitive use of the same promoter within one transgene stack to obtain similar levels of expression patterns of different transgenes for expression of a single polygenic trait. Multi-gene constructs driven by the same promoter are known to cause gene silencing resulting in less efficacious transgenic products in the field. Excess of transcription factor (TF)-binding sites due to promoter repetition can cause depletion of endogenous TFs leading to transcriptional inactivation. The silencing of transgenes will likely undesirably affect performance of a transgenic plant produced to express transgenes. Repetitive sequences within a transgene may lead to gene intra locus homologous recombination resulting in polynucleotide rearrangements.

It is desirable to use diversified promoters for the expression of different transgenes in a gene stack. In an embodiment, diversified constitutive ubiquitin obtained from different plant species can drive transcription of multiple transcription units, including RNAi, artificial miRNA, or hairpin-loop RNA sequences.

Provided are methods and constructs using a constitutive ubiquitin (Ubil) promoter to express non-ubiquitin transgenes in plant. In an embodiment, a promoter can be the Brachypodium distachyon ubiquitin 1 C (UbilC) promoter.

CTGCTCGTTCAGCCCACAGTAACACGCCGTGCGACATGCAGATGCCC TCCACCACGCCGACCAACCCCAAGTCCGCCGCGCTCGTCCACGGCGC CATCCGCATCCGCGCGTCAACGTCATCCGGAGGAGGCGAGCGCGATG TCGACGGCCACGGCGGCGGCGGACACGACGGCGACGCCCCGACTCC GCGCGCGCGTCAAGGCTGCAGTGGCGTCGTGGTGGCCGTCCGCCTGC ACGAGATCCCCGCGTGGACGAGCGCCGCCTCCACCCAGCCCCTATAT CGAGAAATCAACGGTGGGCTCGAGCTCCTCAGCAACCTCCCCACCCC CCCTTCCGACCACGCTCCCTTCCCCCGTGCCCCTCTTCTCCGTAAACC CGAGCCGCCGAGAACAACACCAACGAAAGGGCGAAGAGAATCGCCA TAGAGAGGAGATGGGCGGAGGCGGATAGTTTCAGCCATTCACGGAG AAATGGGGAGGAGAGAACACGACATCATACGGACGCGACCCTCTAG CTGGCTGGCTGTCCTAAAGAATCGAACGGAATCGCTGCGCCAGGAGA AAACGAACGGTCCTGAAGCATGTGCGCCCGGTTCTTCCAAAACACTT ATCTTT A AG ATTG A AGT AGTAT AT ATG ACTG A A ΑΤΤΤΤΤ AC A AGGTTT TTCCCCATAAAACAGGTGAGCTTATCTCATCCTTTTGTTTAGGATGTA CGT ATT AT AT ATG ACTG A AT ΑΤΤΤΤΤΤ ATTTTC ATTG A ATG A AG ΑΤΤΤΤ CGACCCCCCAAAAATAAAAAACGGAGGGAGTACCTTTGTGCCGTGTA TATGGACTAGAGCCATCGGGACGTTTCCGGAGACTGCGTGGTGGGGG CGATGGACGCACAACGACCGCATTTTCGGTTGCCGACTCGCCGTTCG CATCTGGTAGGCACGACTCGTCGGGTTCGGCTCTTGCGTGAGCCGTG ACGTAACAGACCCGTTCTCTTCCCCCGTCTGGCCATCCATAAATCCCC CCTCCATCGGCTTCCCTTTCCTCAATCCAGCACCCTGATT (SEQ ID

ΝΟ:1)

In an embodiment, a promoter can be the Brachypodium distachyon ubiquitin 1 (Ubi 1) promoter.

GGCGTCAGGACTGGCGAAGTCTGGACTCTGCAGGGCCGAACTGCTGA AGACGAAGCAGAGGAAGAGAAAGGGAAGTGTTCGACTTGTAATTTG GTTGGAAAAACGATGCTGGCTGGTTGGGCTGGGCCGATGTACGCTTG CAAACAACTTGTGGCGGCCCGTTCTGGACGAGCAGGAGTTTCTTTTTT GTTCTCACTTTTCTGGTCTTCTTT AGTT ACGGAGTACCTTTTGTTTTTT A A AGG AGTT ACCTTTTTTTT AGG A ATTCTTT AGTT ACCTTTCGCTTGCT CTCAAAAAATATTTAACTTTCGCTTTTTTTCATTTTAATTTTTGCAACT ATTTACGAGTTTCATGAATGCTTATTTTCCAGCATATCATTATTTGCA AGTATTTTTATGCCGTATGTATTGGACGAGAGCCATCGGGACTGTTCC AGAGACTGCGTGGTGGGGACGGCTCCCAACCGCCTTTTCTATCTCTGT TCGCATCCGGTGGCCGACTTGGCTCGCGCGTGAGCCGTGACGTAACA GACTTGGTCTCTTCCCCATCTGGCC ATCTATA AATTCCCCCATCGATC GACCCTCCCTTTCC (SEQ ID ΝΟ:2)

In an embodiment, a promoter can be the Setaria italica ubiquitin 2 (Ubi2) promoter.

TGCGTCTGGACGCACAAGTCATAGCATTATCGGCTAAAATTTCTTAAT TTCTA AATTAGTC ATATCCiGCTA AGAAAGTGGGCiAGC ACTATC ΑΤΤΤ CGTAGAACAAGAACAAGGTATCATATATATATATATATATAATATTT AAACTTTGTTAAGTGGAATCAAAGTGCTAGTATTAATGGAGTTTCAT GTGCATTAAATTTTATGTCACATCAGCAATTTTGTTGACTTGGCAAGG TC ΑΤΤΤ AGGGTGTGTTTGG A AG AC AGGGGCT ATT AGG AGT ATT A A AC ATAGTCTAATTACAAAACTAATTGCACAACCGCTAAGCTGAATCGCCi AGATGGATCTATTAAGCTTAATTAGTCCATGATTTGACAATGTGGTGC TACAATAACCATTTGCTAATGATGGATTACTTAGGTTTAATAGATTCG TCTCGTGATTTAGCCTATGGGTTCTGCTATTAATTTTGTAATTAGCTCA TATTTAGTTCTTATAATTAGTATCCGAACATCCAATGTGACATGCTAA AGTTTAACCCTGGTATCCAAATGAAGTCTTATGAGAGTTTCATCACTC CGGTGGTATATGTACTTAGGCTCCGTTTTCTTCCACCGACTTATTTTTA GCACCCGTCACATTGAATGTTTAGATACTAATTAGAAGTATTAAACG Τ AG ACTATTT AC A A A ATCC ATT AC AT A AG ACG A ATCT A A ACGG CG AG ACGA ATCT ATT ΑΑ ACCT A ATT AGTCC ATGATTTG AC A ATGTGTTGCTA CAGTAAACATTTGCTAATGATGGATTAATTAGGCTTAATAGATTCGTC TCGCCGTTTAGCCTCCACTTATGTAATGGGTTTTCTAAACAATCTACG TTTAATACTCCTAATTAGTATCTAAATATTCAATGTGACACGTGCTAA AAATAAGTCAGTGGAAGGAAGAGAACGTCCCCTTAGTTTTCCATCTT ATTAATTGTACGATGAAACTGTGCAGCCAGATGATTGACAATCGCAA TACTTCAACTAGTGGGCCATGCACATCAGCGACGTGTAACGTCGTGA GTTGCTGTTCCCGTAG (SEQ ID ΝΟ:3)

In an embodiment, a promoter can be the Panicum virgatum (Switchgrass) ubiquitin 1 promoter.

TTGAATTTTAATTTCAAATTTTGCAGGGTAGTAGTGGACATCACAATA CAT ΑΤΤΤ AG A A A A AGTTTT AT A ATTTTCCTCCGTT AGTTTTCAT AT A AT TTTGAACTCCAACGATTAATCTATTATTAAATATCCCGATCTATCAAA ATAATGATAAAAATTTATGATTAATTTTTCTAACATGTGTTATGGTGT GT ACTATCGTCTTAT A A A ATTTC A ACTT A A A ACTCC ACCTAT ACATGG AGAAATGAAAAAGACGAATTACAGTAGGGAGTAATTTGAACCAAAT GGAATAGTTTGAGGGTAAAATGAACTAAACAATAGTTTAGGAGGTTA TTCAGATTTTAGTTATAGTTGAGAGGAGTAATTTAGACTTTTTCCTAT CTTGAATTGTTGACGGCTCTCCTATCGGATATCGGATGGAGTCTTTCA GCCCAACATAACTTCATTCGGGCCCAAACGTTCGTCCATCCAGCCTA CT GGT ATT ATAGG AGGG A A AT AT AC A ACGTGTTC ACCTTTGGTTTC AT TCTTGTTCCATCTGAATTTATCTAAAACTGTGTTTGAACTTCGTAAGA ATTTTGTTCGATCTGTCCGGTACATCGTGTTGATAGGTGGCCTCCGAG ATTCTTCTTTTTAACCGGCAAAGTAAAATAATCTCAGCTCCAGCCTAA CGTCAATTATCAGAGAGAGAAAAAAATATTTTTTTATGATTGATCGG AAACCAACCGCCTTACGTGTCGATCCTGGTTCCTGGCCGGCACGGCG GAGGAAAGCGACCGACCTCGCAACGCCGGCGCACGGCGCCGCCGTG TTGGACTTGGTCTCCCGCGACTCCGTGGGCCTCGGCTTATCGCCGCCG CTCCATCTCAACCGTCCGCTTGGACACGTGGAAGTTGATCCGTCGCGC ACC AGCCTCGG AGGT A ACCT A ACTGCCCGT ACT ΑΤΑ A ATCCGGGATC CGGCCTCTCCAATCCCCATCGCCA (SEQ ID ΝΟ:35)

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter.

In an embodiment, the ubiquitin promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter. In an embodiment, a nucleic acid construct is provided comprising a promoter, wherein the promoter is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35. In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter that is operably linked to a polylinker. In an embodiment, a gene expression cassette is provided comprising a ubiquitin promoter that is operably linked to a ηοηubiquitin transgene. In one embodiment the promoter consists of SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin promoter that is operably linked to the 5' end of a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In addition to a promoter, a 3’-untranslated gene region (i.℮., 3’UTR) or terminator is needed for transcription termination and polyadenylation of the mRNA. Proper transcription termination and polyadenylation of mRNA is important for stable expression of transgene.

The transcription termination becomes more critical for multigene stacks to avoid transcription read-through into next transgene. Similarly, non-polyadenylated aberrant RNA (aRNA) is a substrate for plant RNA-dependent RNA polymerases (RdRPs) to convert aRNA into double stranded RNA (dsRNA) leading to small RNA production and transgene silencing. Strong transcription terminators therefore are very useful both for single gene and multiple gene stacks. While a promoter is necessary to drive transcription, a 3’-UTR gene region can terminate transcription and initiate polyadenylation of a resulting mRNA transcript for translation and protein synthesis. A 3’-UTR gene region aids stable expression of a transgene.

In accordance with one embodiment a nucleic acid construct is provided comprising a ubiquitin transcription terminator. In an embodiment, the ubiquitin transcription terminator is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin transcription terminator. In an embodiment, a nucleic acid construct is provided comprising a transcription terminator, wherein the transcription terminator is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36. In an embodiment, a nucleic acid construct is provided comprising a ubiquitin transcription terminator that is operably linked to a polylinker. In an embodiment, a gene expression cassette is provided comprising a ubiquitin transcription terminator that is operably linked to the 3’ end of a non-ubiquitin transgene. In one embodiment the transcription terminator consists of SEQ ID NO: 4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin transcription terminator that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In one embodiment a nucleic acid vector is provided comprising a transcription terminator operably linked to either a polylinker sequence, a non-ubiquitin transgene or a combination of both, wherein the transcription terminator comprises SEQ ID NO: 4 or a sequence that has 90% sequence identity with SEQ ID NO: 4. In one embodiment the transcription terminator is less than lkb in length, and in a further embodiment the transcription terminator consists of the 3’UTR sequence of SEQ ID NO: 4.

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein and a 3’-UTR. In an embodiment, the nucleic acid construct comprises a ubiquitin 3’-UTR. In an embodiment, the ubiquitin 3’-UTR is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 3’-UTR. In an embodiment, a 3’-UTR can be the Brachypodium distachyon ubiquitinl C (UbilC) 3’-UTR.

GTTTGTCAAAAACTGGCCTACAGTCTGCTGCCCCTGTTGGTCTGCC.CC TTGGAAGTAGTCGTGTCTATGGTTATGTGAGAAGTCGTTGTGTTCTTT CTAATCCCGTACTGTTTGTGTGAACATCTGCTGCTGTCGTATTGCATC GTGAAGAATCCTGTTATGAATAAGTGAACATGAACCTTGTTCTGTGA TTACGGCTTCGTGGTTATGCGAACGTTCTTACAAACGCAATTGCACCT GATGTAAAATCGTTTTTGCTAGCTGTATGGAACAAGTGCTCATGATGT TCATGCAAGATGCAATTCCAGCTTTTGTTGGTTTGTCATCTTTGTACT GTGCTTACCGCACATAAAGATTGCATCTTGCTTATTGC.TTTGTTGCTTT GGTGCTCGTCCGCTTCTCCTTGCACCTTATCAAACCTTTGTTTAGATTC TTCTGAAATTTCATGACTGATAAAGCTGATAGATGGAGTACTAATAT ATGACATCTTTCCATAAATGTTCGGGTGCAGAGATATGGAGGCCCCA GGATCCTATTTACAGGATGAACCTACCTGGGCCGCTGTACGCATGAC ATCCGCGAGCAAGTCTGAGGTTCTCAATGTACACATGAAATTGATTTT TGCTGCGTTTGGCTTGGCTGATCGTTGCATTTGTTCTGATTCATCAGA GTTAAATAACGGATATATCAGCAAATATCCGCAGCATCCACACCGAC CACACGTCCGGTTAACAGAGTCCCCCTGCCTTGCTTTAATTATTACGG AGT ACTCCGCT ATT A ATCCTT AG AT ATGTTTCG A AGG A ACTC A A ACCT TCCTCCATCTGCAAATCTCAGTGCTTCAAAACTGGAATTAGATAATTG AAACCTTCATTCGGTTGC AATTCACAACTGC AAATTGAACAGCACTG TCAATTTCAATTTCGGGTTCACGATTCCACCGATAGGTTGACATGATC CATGATCCACCCATTGTACAAC (SEQ ID ΝΟ:4)

In an embodiment, a 3’-UTR can be the Brachypodium distachyon ubiquitin 1 (Ubil) 3’-UTR.

GCTTCTGCCG A ACTGGTTC AC AGTCTGCTGCCCTTGGTGGTCTGCCCC TTAGTGGTCATGCCTTTTGTTATGTGTCTTGCGTCCCAATCCTGTATCG TTTGTGTGAACATCTCTGCTGCTGTATAGCAGCTTGAATCCTGTTATG AATTTGTGAACCTGAACCTTGTTCCGTGAATCATGTTATGAATAAGTG AACCTGAACCTTGTTCCGTGATTATTGTTACAATCTGTTGTGCCGTAT GGTTGGTCGTGTGTGATTTATGTTGAACTGGAGAACCAAGTTCGTTCC AGG AC AT ATTGC A ACCT A AGCT A A ACC ATGT AG A ACT ACTTGTTCTG GGAGACATAAAACGTCATTTTTATGCATTCGTAACATTTAAGCATACT ACAATAATTGTATTGTCCTTTTCCTACTCATCCTTGAAACCATATGCC TCTTCTCAGCGCCTCTACATGCAGTGTGCTCAGAACAAACAGGCCCT GCCAGCTGCTTTTCAATTTTCCAATTAATAACCACAATAGTCGGACTA TGGCATCTGTGGGTGACTATGCAAGATGTTGCTGTCAGGTCTCTGAA ACTTTTCCC ATGT ATCTGTTGAAATTACCC AGT AAATTC ATGCCTCT A TTTAATCTGGCATGGTTGATTTTCAAACAGAATGTGTTTTTTTTTGTTC Τ GG A AGCT AT ATTGGT A A AT A A AT AC A A AGCT GG AGTGTG ΑΤΤΑΤ AT TTCCAACAGATATTCAAGAAAATCTCAGTTGATTTATTTACTACTGTA GTAT ΑΤΑΤ AT ATATCTT AC AGTTG ACTTCTC ATATTTC A A ACG AC ATG TGAGCACATTGTTCAGTTTCTTAGGATGTGTTGTGTGCTCAAAGGTGT AATTTTGCATTCTGCCCTCCGAGTAAACACTACACGTATTTTTTTGAG TGGCAGTGCATTTGATTACAAGGCAACAACAACAAAAACCTATGGCA AGATATCCTTCTTAGAGGCTGCCAGGATCATTTTGACTGAACTATGTA AGGCTGAAGAAAAGG (SEQ ID ΝΟ:5)

In an embodiment, a 3^!-UTR can be the Setaria ilalica ubiquitin 2 (Ubi2) 3’-UTR.

GCCCATCGGTCATGGATGCTTCTACTGTACCTGGGTCGTCTGGTCTCT GCCTGTGTCACCTTTGAAGTACCTGTGTCGGGATTGTGTTTGGTCATG AACTGCAGTTTGTCTTTGATGTTCTTTTGTCTGGTCTTATGAACTGGTT GTATCTGTATGTTTACTGTAAACTGTTGTTGCGGTGCAGCAGTATGGC ATCCGAATGAATAAATGATGTTTGGACTTAAATCTGTACTCTGTTTGT TTTCGGTT ATGCC AGTTCT AT ATTGCCTG AGATC AG AATGTTT AGCTT TTGAGTTCTGTTTGGCTTGTGGTCGACTCCTGTTTCTTACTTGAGGCGT AACTCTGTTCTGGCAAACTCAAATGTCTAACTGAATGTTTTAGGACTT AATTGTTGGACAGATTAACGTGTTTGGTTTGTTTCTAGATTGTGATTC GGAAGGCTTGTTAGTTGTGGAATCAAGGAGAGCAGCTAGGTCTGTGC AG AACGTTATTTTGGATTTAAGCCTTCTCAGATTATGCC ATTACTCTA AACCTAATGATATCATATTTCACTCGGGGATGTTGGAGTAGTCTTTTC TTTCTCCTGCAGACAAAATGATTTTGCTTTCGTGTGTGTACATGATTTT GTGCAACTGTTGCAACAACTGAAGTAGACAAGTTTTGACCTCACCAG A AG A ATG A A A A AG ATTTTGG A ATTTGTT AC ATCG ACA A ACCATTGT A ACTTGGCCCATCAGAATGCACAGAAGAGCGGCTACAAATTGACATGC GTTGCAAACTTTGCAATAGTTGATGCACATGTTTGCCATTGCCTGCCA GTCTT AGG A A A AGTGTGTGGTTCG AG A A ATCT A AGC ATATGTGCTCT GCTCACATTGCGTGGAACCCACACAGCTTTGTCACACTCTTGTCCACT CCAGAAGTCATTCCTGGCGCTGTTTACCCCTGGTAAAAGGTAACCGA AAACTTCTC AAGGCTGTACCCAAAACTGGAAGGAAATTTGGAGGAAA TCTTTGCTTTTGATCGGCTCACTCTTTC(SEQ ID ΝΟ:6)

In an embodiment, a 3’ -UTR can be the Panicum virgatum (Switchgrass) ubiquitin 1 3’ -UTR.

GCCTAGTGCTCCTGAGTTGCCTTTTGTCGTTATGGTCAACCTCTGGTTT A AGTCGTGTG A ACTCTCTGC ATTGCGTTGCTAGTGTCTGGTTGTGGTT GTAATAAGAACATGAAGAACATGTTGCTGTGGATCACATGACTTTTT TTTTTGAACCGGAAGATCACATGACTTTCATGGCTTTAAGTTCCTGAA CTCTGAAATCTGGACCCCTTTTTAAGCTCTGAACTCATCATTCTTGCA TTTACATCTGGTGTTGATCTTATTGATGTGATGCAGTCCTGCTGAAAT AGTCAATGTAGATTCATGACTGACTGATTGCGTTTATGGTGTGTATGT TGTTAACAAGCTGAAGGTCGTGTGGTGTCTTTCCAGTTAGACGAAGT GTGCTTTATTGTAGCGTGTAGTGCTGCTGGATGATTGATGAACTGAAA CATTCTGCATTTAGCAACTAGCGAGCCAAAGGTGATGACTGAGTTTC, TGTAGACCTGTTTTTTTATGCCCATGGTCGTTCTTCAATTGCACTTGAT TTTCACATTAGCTGGATCATAATCTGAGCAGACTACTCAAAAGTACA AAGTTCATCTTCGCTATGACGCTTTGCCACTAGGATTTTCTTTGTATG ATTTGTTTACAAATCCTGTAATCTAGTCAAAAGAAAAGCCAAAATTTT TCTTTGTATGATTTGTTTACAAATCCTCTAATCTAGTCAAAGAAAAGC CAAATTTATCCCTCCTGGTCCCCTACATCACGTAGCTATGTGGCCCGC AAGCAGATGAAAGCAGCCCCGTCAGCCGACGCCGACGCCGACGCCA ACACATCCTGCTCCTCCCTCGCCGGCGCCGGCGCCGGCGAGGCCGCA CCGCCGCTGCCCCGTGGCCGCAGGCACACGGTGCCGCACTGCCGCCG CCCCGTGGCCGCAGGCACACGGTGCCGCACTGCCGCCGCCTCCCCTT CCGGCATTGCCGGACGGCTGGGCTACTGTCCCCGCCGCCTTCCCAAT( SEQ ID ΝΟ:36)

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein and a 3’-UTR, wherein the 3’-UTR is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36. In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein and the 3’-UTR wherein the ubiquitin promoter and 3-UTR are both operably linked to opposite ends of a polylinker. In an embodiment, a gene expression cassette is provided comprising a ubiquitin promoter as described herein and a 3’-UTR, wherein the ubiquitin promoter and 3’-UTR are both operably linked to opposite ends of a non-ubiquitin transgene. In one embodiment the a 3’-UTR, consists of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36. In one embodiment, a gene expression cassette is provided comprising a ubiquitin promoter as described herein and a 3’-UTR, wherein the ubiquitin promoter comprises SEQ ID NO: 2Α and the 3'-UTR comprises SEQ ID NO: 4 wherein the promoter and 3'-UTR are operably linked to opposite ends of a non-ubiquitin transgene. In one embodiment the a 3’-UTR, consists of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36. In one embodiment the promoter consists of SEQ ID NO: 2Α, 15 or 40 and the 3’-UTR, consists of SEQ ID ΝΟ:4. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin 3’-UTR that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In a further embodiment the transgene is operably linked to a ubiquitin promoter and a 3’-UTR from the same ubiquitin gene isolated from Panicum virgatum, Bmehypoclium clistachyon, or Setaria italica.

In one embodiment a vector is provided comprising a first transgene and/or polylinker and a second transgene and/or polylinker wherein the first transgene and/or polylinker is operably linked to a promoter comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, and SEQ ID ΝΟ:35 and operably linked to a 3’-UTR, comprising a sequence selected from the group consisting of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36 and the second transgene and/or polylinker is operably linked to a promoter comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, and SEQ ID ΝΟ:35 and operably linked to a 3’-UTR, comprising a sequence selected from the group consisting of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36, further wherein the promoter of the first transgene and/or polylinker and second transgene and/or polylinker are derived from Ubi genes from different plant species. In a further embodiment the vector is provided with a third transgene and/or polylinker wherein the third transgene and/or polylinker polylinker is operably linked to a promoter comprising a sequence selected from the group consisting of SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, and SEQ ID ΝΟ:35 and operably linked to a 3’-UTR, comprising a sequence selected from the group consisting of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36, further wherein the promoter of the third transgene and/or polylinker is derived from Ubi genes from a different plant species from the promoter of the first and second transgene and/or polylinker.

Transgene expression may also be regulated by an intron region located downstream of the promoter sequence. Both a promoter and an intron can regulate transgene expression. While a promoter is necessary to drive transcription, the presence of an intron can increase expression levels resulting in mRNA transcript for translation and protein synthesis. An intron gene region aids stable expression of a transgene.

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein and an intron. In one embodiment the intron is operably linked to the 3' end of the promoter. In an embodiment, a nucleic acid construct is provided comprising a ubiquitin intron operably linked to the 3' end of a ubiquitin promoter isolated from Panicum virgatum, Brachypodium distachyon or Setaria italica or a derivative of such promoter sequence. In an embodiment, the ubiquitin intron is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin intron, or a derivative of such intron sequence.

In an embodiment, an intron can be the Brachypodium distachyon ubiquitin 1 C intron.

GTATGCAGCCTCGCTTCCTCCTCGCTACCGTTTCAATTCTGGAGTAGGTCGTAGAGGA TACCATGTTGATTTGACAGAGGGAGTAGATTAGATACTTGTAGATCGAAGTGCGGAT GTTCCATGGTAGATGATACCATGTTGATTTCGATTAGATCGGATTAAATCTTTGTAGA TCGAAGTGCGCATGTTCCATGAATTGCCTGTTACCAGTAGATTCAAGTTTTTCTGTGT TATAGAGGTGGGATCTACTCGTTGAGATGATTAGCTCCTAGAGGACACCATGCCGTT TTGGAAAATAGATCAGAACCGTGTAGATCGATGTGAGCATGTGTTCCTGTAGATCCA AGTTCTTTCGCATGTTACTAGTTGTGATCTATTGTTTGTGTAATACGCTCTCGATCTAT CCGTGTAGATTTCACTCGATTACTGTTACTGTGGCTTGATCGTTCATAGTTGTTCGTTA GGTTTGATCGAACAGTGTCTGAACCTAATTGGATATGTATTCTTGATCTATCAACGTG TAGGTTTCAGTCATGTATTTATGTACTCCCTCCGTCCCAAATTAACTGACGTGGATTT TGTATAAGAATCTATACAAATCCATGTCAGTTAATTCGGGATGGAGTACCATATTCA ATAATTTGTTTATTGCTGTCCACTTATGTACCATATGTTTGTTGTTCCTCATGTGGATT CTACTAATTATCATTGATTGGTGATCTTCTATTTTGCTAGTTTCCTAGCTCAATCTGGT TATTCATGTAGATGTGTTGTTGAAATCGGAGACCATGCTTGTTATTAGATAGTTTATT GCTTATCAGTTTCATGTTCTGGTTGATGCAACACATATTCATGTTCGCTATCTGGTTG CTGCTTGATATTCTCTGATTTACATTCATTATAAGAATATATTCTGCTCTGGTTGTTGC TTCTCATGACTTTACCTACTCGGTAGGTGACTTACCTTTTGGTTTACAATTGTCAACTA TGCAG (SEQ ID ΝΟ:7)

In an embodiment, an intron can be the Brachypodium distachyon ubiquitin 1 (Ubil) intron

GTATGTAGCCTCTCGATTCCTCCTCAGCCCTGCCCTCGATTTGGTGTACGCGTTGAGA TGATG ATCTCGT AG ATGTCT AG ATG AC ACC ATGTCG ATTTG A A AT AG ATC AG ATCCG TGTAGATCGATGAGCTCCTGTGTACCTGTGGATTCAAGTTATTTTCGCATGCTATTGT TGTG ATCTACT AG ATCT AGTGTGTGTATTCT ATGCTATCG ATTTCTCCGTGTAG ATTTC ACTCGATTACTGTTACTGTGGCTTGATCGGCCATAGATGTTGGTTAAGGTTTGATCGG TTAGTGTTTGAACCTGCGTGGATATCTAGCATCCATCTATTATCGTGTAGGTTTCGAA CAAACAAGCACTATTATTGTACTGATGGTTCGTCTATGGTTGGTTTTGACCGTTTTAG TGTTGAACGAGCCTTCTGTATTTGTTTATTGCTGTCCAGTGATGTACCATGTTCGTTG AGTGTCGGATTATACTAATTATTGTTGATTGATAATCTTGTAGTTTGCTTTTCCTAATT TATTTATCGTAGTCCTGATTTGCCTCAGCTGTGCCTCACCCGTGCGATGGTCAATCAA CTTGTT AGCCC A ATCTGCTTA ATC ATGT AC ATTTGTTGTT AG A ATC AG AG ATC A AGCC AATTAGCTATCTTATTGCTTATCTGTTCCATGTTCTGATCGATGTAACAGTCTACACTT TTGCTCTGTGCTACTTGATTAAAACATTCTGACTTAAATTCATGATTGGAAGTTTCAG ATCTG ATTGTTGCCTT ACTTG ACTA ATATCT ATTC ATGTCi AC ACCTCTCTGTCTTGGT A ACTTACCGCTGTTTGTTTGTAATTTCTGACTATGCAG (SEQ ID NO:8)

In an embodiment, an intron can be the Setaria italica ubiquitin 2 (Ubi2) intron 1 GTCACGGGTTCCTTCCCCACCTCTCCTCTTCCCCACCGCCATAΑΑΤAG (SEQ ID ΝΟ:9)

In an embodiment, an intron can be the Setaria italica ubiquitin 2 (Ubi2) intron 2

GTACGGCGATCGTCTTCCTCCTCTAGATCGGCGTGATCTGCAAGTAGTTGATTTGGTA G ATGGTT AGG ATCTGTGCACTG A AG ΑΑ ATC ATGTT AG ATCCGCG ATGTTTCTGTTCGT

CACGCTCCTGCGATTTGTGGGGATTTTAGGTCGTTGATCTGGGAATCGTGGGGTTGCT TCTAGGCTGTTCGTAG ATG AGGTCGTTCTCACGGTTTACTGGATCATTGCCTAGTAG A TCAGCTCGGGCTTTCGTCTTTGTATATGGTGCCCATACTTGCATCTATGATCTGGTTCC GTGGTGTTACCTAGGTTTCTGCGCCTGATTCGTCCGATCGATTTTGTTAGCATGTGGT AAACGTTTGGTCATGGTCTGATTTAGATTAGAGTCGAATAGGATGATCTCGATCTAG CTCTTGGG ATT A AT ATGC ATGTGTC ACC A ATCTGTTCCGTGGTT A AGATGATG A ATCT ATGCTTAGTTAATGGGTGTAG AT AT AT ATGCTGCTGTTCCTC A ATGATGCCGTAGCTT TTACCTGAGCAGCATGGATCCTCCTGTTACTTAGGTAGATGCACATGCTTATAGATCA AGATATGTACTGCTACTGTTGGAATTCTTTAGTATACCTGATGATCATCCATGCTCTT GTTACTTGTTTTGGTATACTTGGATGATGGCATGCTGCTGCTTTTTGTTGATTTGAGCC CATCCATATCTGCATATGTCACATGATTAAGATGATTACGCTGTTTCTGTATGATGCC ATAGCTTTTATGTGAGCAACATGCATCCTCCTGGTTATATGCATTAATAGATGGAAG ATATCTATTGCTACAATTTGATGATTATTTTGTACATACGATGATCAAGCATGCTCTT C ATACTTTGTTGAT AT ACTTGGAT A ATG ΑΑ ATGCTGCTGC ACGTTC ATTCT AT AGC AC TAATGATGTGATGAACACGCACGACCTGTTTGTGGCATCTGTTTGAATGTGTTGTTGC TGTTCACTAGAGACTGTTTTATTAACCTACTGCTAGATACTTACCCTTCTGTCTGTTTA TTCTTTTGCAG (SEQ ID NO: 10)

In an embodiment, an intron can be the Panicum virgatum (Switchgrass) ubiquitin intron.

GTACTCCTACCTAATCCTCCTTAACTGATCTCTCCTCTATCACGTTGGTAATCTTCGA ATGATCTGCTGCCTGGCTCGCTGTTCCCCCTCGTTATGCACTGTTTCCATCACGAGT TTTTTTTTTCATCATCTAATCTATGCGGTTGCGGAAGAATTGTGGCTAGTGGAGTAG TTTTCTGTGCTTGATCGGTAGATTCGATGTGTGGGTGTATGGATGTTTTCTGAAAAG TTGCTGGATTAGTTTACGCTTTCAGGCCGCAGGTCTGTTCGAAATTGATTATGAAGT CTATATGCTTTGGATCTATCGATTTCCAGTTTTATTCAGATGTAGGCCAAAAAATTG TCGGCATTTGTGTGGAATTAGTTGGCCTTTAGGTCTGCACATTCATGGTGACGGCAC AGTTGCTGCTGGCTGTTGCGTGGGACGAGTTATTATAGTTGTTTTTGTTTTTCCCTG ATTG ATTC AC ATTTTC A ATG AT A ACT AGCCTTTGTC ACCTAACCAAGTCC AGGTTGA TCCTATCTGTGTTCTTCAGCTACCAGTTTGCATAGATGATGGTGTATTCGATTGCTTT AGT AGGCCTTCTG ATTTC AC ATCT A ATTCTGTC ATG A AT AT AG AT A ACTTT AC ATGC TTTTGATATACTTTATATTTGAACTGTTCACTGTCCAGCCTATTTTGGATAATTGAGT GCATTGGCTTTTGATGCCTGAATTATTCACATGTTCCTGGATAATTGACCTGTGTCA CCTAGTTGACTGTTTTTTGAGGTGCCACCCGTCTGTTCAGCTGATTTGTGTATTCGA TTGCTCTAGTTAATCTTTTGATTATGCAGCTAGTGCTTTGTCATATGTAGCTTTATAG GCTTCTGATGTCCTTGGATATAGTTCAGTCTACTTGTCAAGTTGCTTTACAAGTAGT AGCTCTG ATTCT ATTTGGCTTCCTG AGTC AG AGCTTTGC A A ATTGCTTGTTGTT AC A ΤΤ AC ATC AT ATT ACTTG A ATTGC AGTT ΑΤΤΤ A ATGGTTGG ATTGTTGCTGTTTACTTC Τ AC ATTTTTTGCTGTTTTAT ATT AT ACT A ΑΑ ATGTTTGTGTTGCTGCTTTTC AG (SEQ ID ΝΟ:37)

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein and an intron, wherein the intron is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37. In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein, an intron sequence and a polylinker wherein the promoter and intron are operably linked to a polylinker. In an embodiment, a gene expression cassette is provided comprising a ubiquitin promoter as described herein, an intron sequence and a non-ubiquitin transgene wherein the promoter and intron are operably linked to the 5' end of the transgene. Optionally the construct further comprises a 3’UTR that is operably linked to the 3’ end of the non-ubiquitin transgene or polylinker. In one embodiment the promoter and 3’-UTR sequences are selected from those described herein and the intron sequence consists of SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37. In an embodiment, a gene expression cassette comprises a ubiquitin intron that is operably linked to a promoter, wherein the promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter, or a promoter that originates from a plant (e.g., Zea mays ubiquitin 1 promoter), a virus (e.g., Cassava vein mosaic vims promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an illustrative embodiment, a gene expression cassette comprises a ubiquitin intron that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

Transgene expression may also be regulated by a 5’-UTR region located downstream of the promoter sequence. Both a promoter and a 5’-UTR can regulate transgene expression. While a promoter is necessary to drive transcription, the presence of a 5’-UTR can increase expression levels resulting in mRNA transcript for translation and protein synthesis. A 5’-UTR gene region aids stable expression of a transgene.

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as described herein and a 5’-UTR. In one embodiment the 5’-UTR is operably linked to the 3’ end of the promoter. In an embodiment, a nucleic acid construct is provided comprising a ubiquitin a 5’UTR operably linked to the 3' end of a ubiquitin promoter isolated from Panicum virgatum, Brachypodium distachyon or Setaria italica or a derivative of such promoter sequence. In a further embodiment the 3' end of the 5’-UTR is operably linked to the 5’ end of a ubiquitin intron from Panicum virgatum, Brachypodium distachyon or Setaria italica, as described herein.

In an embodiment, a 5’-UTR can be the Brachypodium distachyon ubiquitinl C (UbilC) 5’-UTR.

CCGATCGAAAAGTCCCCGCAAGAGCAAGCGACCGATCTCGTGAATCTCCGTCAAG (SEQ ID NO: 11)

In an embodiment, a 5’-UTR can be the Brachypodium distachyon ubiquitin 1 (Ubil) 5’UTR.

CCAATCCAGCACCCCCGATCCCGATCGAAAATTCTCCGCAACAGCAAGCGATCGATC TAGCGAATCCCCGTCAAG (SEQ ID NO: 12)

In an embodiment, a 5’-UTR can be the Setaria italica ubiquitin 2 (Ubi2) 5’-UTRl

AGAAATATCAACTGGTGGGCCACGCACATCAGCGTCGTGTAACGTGGACGGAGGAG CCCCGTGACGGCGTCGACATCGAACGGCCACCAACCACGGAACCACCCGTCCCCACC TCTCGGAAGCTCCGCTCCACGGCGTCGACATCTAACGGCTACCAGCAGGCGTACGGG TTGGAGTGGACTCCTTGCCTCTTTGCGCTGGCGGCTTCCGGAAATTGCGTGGCGGAG ACGAGGCGGGCTCGTCTCACACGGCACGGAAGAC (SEQ ID NO: 13)

In an embodiment, a 5’-UTR can be the Setaria italica ubiquitin 2 (Ubi2) 5’-UTR2 CCGACCCCCTCGCCTTTCTCCCCAATCTCATCTCGTCTCGTGTTGTTCGGAGCACACC ACCCGCCCCAAATCGTTCTTCCCGCAAGCCTCGGCGATCCTTCACCCGCTTCAAG (SEQ ID NO: 14)

In an embodiment, a 5’ -UTR can be the Panicum virgatum (Switchgrass) ubiquitin 5’ UTR.

CAAGTTCGCGATCTCTCGATTTCACAAATCGCCGAGAAGACCCGAGCAGAGAAGTT CCCTCCGATCGCCTTGCCAAG (SEQ ID ΝΟ:38).

In an embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter as disclosed herein and a 5’-UTR, wherein the 5’-UTR is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID ΝΟ:38. In an embodiment, a nucleic acid construct is provided comprising ubiquitin promoter, wherein the promoter is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35, and a 5’-UTR operably linked to a polylinker. In an embodiment, a gene expression cassette is provided comprising a ubiquitin promoter, wherein the promoter is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35, and a 5’-UTR sequences operably linked to a non-ubiquitin transgene.

Optionally, the construct can further comprise a ubiquitin intron as disclosed herein operably linked to the 3' end of the 5’-UTR and the 5' end of the non-ubiquitin transgene and optionally further comprising a 3’-UTR that is operably linked to the 3' end of the non-ubiquitin transgene. In one embodiment the promoter, intron and 3’-UTR sequences are selected from those described herein and the 5’-UTR sequence consists of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID ΝΟ:38. In one embodiment the 3'-UTR consists of SEQ ID NO: 11.

In an embodiment, a gene expression cassette comprises a ubiquitin 5’-UTR that is operably linked to a promoter, wherein the promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter, or a promoter that originates from a plant (e.g., Zea mays ubiquitin 1 promoter), a vims (e.g., Cassava vein mosaic vims promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an illustrative embodiment, a gene expression cassette comprises a ubiquitin 5’-UTR that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In one embodiment a nucleic acid construct is provided comprising a promoter and a polylinker and optionally one or more of the following elements:

a) a 5' untranslated region;

b) an intron; and

c) a 3’ untranslated region,

wherein

the promoter consists of SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35 or a sequence having 98% sequence identity with SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35;

the 5' untranslated region consists of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID ΝΟ:38 or a sequence having 98% sequence identity with SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID ΝΟ:38

the intron consists of SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37 or a sequence having 98% sequence identity with SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37

the 3' untranslated region consists of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36 or a sequence having 98% sequence identity with SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36; further wherein said promoter is operably linked to said polylinker and each optional element, when present, is also operably linked to both the promoter and the polylinker.

In one embodiment a nucleic acid construct is provided comprising a promoter and a ηοηubiquitin transgene and optionally one or more of the following elements:

a) a 5' untranslated region;

b) an intron; and

c) a 3' untranslated region,

wherein

the promoter consists of SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35 or a sequence having 98% sequence identity with SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID NO: 35;

the 5' untranslated region consists of SEQ ID NO: 11, SEQ ID ΝΟ:12, SEQ ID ΝΟ:13, SEQ ID NO: 14, or SEQ ID ΝΟ:38 or a sequence having 98% sequence identity with SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID ΝΟ:38

the intron consists of SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37 or a sequence having 98% sequence identity with SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37

the 3' untranslated region consists of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36 or a sequence having 98% sequence identity with SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36; further wherein said promoter is operably linked to said transgene and each optional element, when present, is also operably linked to both the promoter and the transgene. In a further embodiment a transgenic cell is provided comprising the nucleic acid construct disclosed immediately above. In one embodiment the transgenic cell is a plant cell, and in a further embodiment a plant is provided wherein the plant comprises said transgenic cells.

In accordance with one embodiment transgene expression is regulated by a promoter operably linked to an intron and 5’-UTR region, wherein the intron and 5’-UTR region are located downstream of the promoter sequence. A promoter operably linked to an intron and 5’-UTR region can be used to drive transgene expression. While a promoter is necessary to drive transcription, the presence of the intron and 5’-UTR can increase expression levels resulting in mRNA transcript for translation and protein synthesis.

In an embodiment, a gene expression cassette comprises a promoter operably linked to a 5’-UTR and intron region. In an embodiment, a gene expression cassette comprises a ubiquitin promoter operably linked to a ubiquitin 5’-UTR and ubiquitin intron. In an embodiment, the ubiquitin promoter operably linked to a 5’-UTR and intron region is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter operably linked to an intron and 5’UTR.

In an embodiment, a promoter operably linked to a 5’-UTR and intron can be the Brachypodium distachyon ubiquitinl C (UbilC) promoter operably linked to an intron and 5’UTR. In one embodiment the promoter comprises or consists of the sequence of SEQ ID NO: 15:

CTGCTCGTTCAGCCCACAGTAACACGCCGTGCGACATGCAGATGCCCTCCACCACG CCGACCAACCCCAAGTCCGCCGCGCTCGTCCACGGCGCCATCCGCATCCGCGCGTC AACGTCATCCGGAGGAGGCGAGCGCGATGTCGACGGCCACGGCGGCGGCGGACAC GACGGCGACGCCCCGACTCCGCGCGCGCGTCAAGGCTGCAGTGGCGTCGTGGTGG CCGTCCGCCTGCACGAGATCCCCGCGTGGACGAGCGCCGCCTCCACCCAGCCCCTA TATCGAGAAATCAACGGTGGGCTCGAGCTCCTCAGCAACCTCCCCACCCCCCCTTC CG ACCACGCTCCCTTCCCCCGTGCCCCTCTTCTCCGTA AACCCG AGCC.GCCG AG ΑΑ CAACACCAACGAAAGGGCGAAGAGAATCGCCATAGAGAGGAGATGGGCGGAGGC GGATAGTTTCAGCCATTCACGGAGAAATGGGGAGGAGAGAACACGACATC-ATACG GACGCGACCCTCTAGCTGGCTGGCTGTCCTAAAGAATCGAACGGAATCGCTGCGCC AGGAGAAAACGAACGGTCCTGAAGCATGTGCGCCCGGTTCTTCCAAAACACTTATC ΤΤΤΑ AG ATTGA AGTAGTATATATG ACTGAA ATTTTTAC AAGGTTTTTCCCCATAAAA CAGGTGAGCTTATCTCATCCTTTTGTTTAGGATGTACGTATTATATATGACTGAATA_{TTTTTTATTTTCATTGAATGAAGATTTTCGACCCCCCAAAAATAAAAAACGGAGGG} AGTACCTTTGTGCCGTGTATATGGACTAGAGCCATCGGGACGTTTCCGGAGACTGC GTGGTGGGGGCGATGGACGCACAACGACCGCATTTTCGGTTGCCGACTCGCCGTTC GCATCTGGTAGGCACGACTCGTCGGGTTCGGCTCTTGCGTGAGCCGTGACGTAACA GACCCGTTCTCTTCCCCCGTCTGGCCATCCATAAATCCCCCCTCCATCGGCTTCCCT TTCCTCAATCCAGCACCCTGATTCCGATCGAAAAGTCCCCGCAAGAGCAAGCGACC GATCTCGTG AATCTCCGTCA AGGT ATGC AGCCTCGCTTCCTCCTCGCT ACCGTTTC A ATTCTGGAGTAGGTCGTAGAGGATACCATGTTGATTTGACAGAGGGAGTAGATTAG ATACTTGTAGATCGAAGTGCGGATGTTCCATGGTAGATGATACCATGTTGATTTCG ATTAGATCGGATTAAATCTTTGTAGATCGAAGTGCGCATGTTCCATGAATTGCCTGT TACCAGT AGATTCAAGTTTTTCTGTGTT AT AGAGGTGGGATCT ACTCGTTG AG ATGA TTAGCTCCTAGAGGACACCATGCCGTTTTGGAAAATAGATCAGAACCGTGTAGATC GATGTGAGCATGTGTTCCTGTAGATCCAAGTTCTTTCGCATGTTACTAGTTGTGATC TATTGTTTGTGTAATACGCTCTCGATCTATCCGTGTAGATTTCACTCGATTACTGTTA CTGTGGCTTGATCGTTCATAGTTGTTCGTTAGGTTTGATCGAACAGTGTCTGAACCT AATTGGATATGTATTCTTGATCTATCAACGTGTAGGTTTCAGTCATGTATTTATGTA CTCCCTCCGTCCCAAATTAACTGACGTGGATTTTGTATAAGAATCTATACAAATCCA TGTCAGTTAATTCGGGATGGAGTACCATATTCAATAATTTGTTTATTGCTGTCCACT TATGTACC AT ATGTTTGTTGTTCCTCATGTGG ATTCT ACT ΑΑΤΤ ATC ATTG ATTGGTG ATCTTCT ATTTTGCT AGTTTCCTAGCTC AATCTGGTT ATTC ATGT AGATGTGTTGTTG AAATCGGAGACCATGCTTGTTATTAGATAGTTTATTGCTTATCAGTTTCATGTTCTG GTTGATGCAACACATATTCATGTTCGCTATCTGGTTGCTGCTTGATATTCTCTGATTT ACATTC ΑΤΤΑΤΑ AG ΑΑΤ AT ATTCTGCTCTGGTTGTTGCTTCTC ATGACTTT ACCT ACT CGGTAGGTGACTTACCTTTTGGTTTACAATTGTCAACTATGCAG (SEQ ID NO: 15)

In an embodiment, a promoter operably linked to 5’-UTR and intron can be the Brachypodium distachyon ubiquitin 1 (Ubil) promoter operably linked to a 5’-UTR and intron. In one embodiment the promoter comprises or consists of the sequence of SEQ ID NO: 16:

GGCGTCAGGACTGGCGAAGTCTGGACTCTGCAGGGCCGAACTGCTGAAGACGAAG CAGAGGAAGAGAAAGGGAAGTGTTCGACTTGTAATTTGTAGGGGTTTTTTTTAGAG GAACTTGTAATTTGTAGGTGGGCTGGCCTCGTTGGAAAAACGATGCTGGCTGGTTG GAGTTTCTTTTTTGTTCTCACTTTTCTGGTCTTCTTT AGTT ACGG AGTACCTTTTGTTT TTTAAAGGAGTTACCTTTTTTTTAGGAATTCTTTAGTTACCTTTCGCTTGCTCTCAAA AAATATTTAACTTTCGCTTTTTTTCATTTTAATTTTTGCAACTATTTACGAGTTTCAT GAATGCTTATTTTCCAGCATATCATTATTTGCAAGTATTTTTATGCCGTATGTATTG GACGAGAGCCATCGGGACTGTTCCAGAGACTGCGTGGTGGGGACGGCTCCCAACC GCCTTTTCTATCTCTGTTCGCATCCGGTGGCCGACTTGGCTCGCGCGTGAGCCGTGA CGTAACAGACTTGGTCTCTTCCCCATCTGGCCATCTATAAATTCCCCCATCGATCGA CCCTCCCTTTCCCCAATCCAGCACCCCCGATCCCGATCGAAAATTCTCCGCAACAGC AAGCGATCGATCTAGCGAATCCCCGTCAAGGTATGTAGCCTCTCGATTCCTCCTCA GCCCTGCCCTCGATTTGGTGTACGCGTTGAGATGATGATCTCGTAGATGTCTAGATG ACACCATGTCGATTTGAAATAGATCAGATCCGTGTAGATCGATGAGCTCCTGTGTA CCTGTGGATTCAAGTTATTTTCGCATGCTATTGTTGTGATCTACTAGATCTAGTGTG TGTATTCTATGCTATCGATTTCTCCGTGTAGATTTCACTCGATTACTGTTACTGTGGC TTGATCGGCCATAGATGTTGGTTAAGGTTTGATCGGTTAGTGTTTGAACCTGCGTGG ATATCTAGCATCCATCTATTATCGTGTAGGTTTCGAACAAACAAGCACTATTATTGT ACTGATGGTTCGTCTATGGTTGGTTTTGACCGTTTTAGTGTTGAACGAGCCTTCTGT ATTTGTTTATTGCTGTCCAGTGATGTACCATGTTCGTTGAGTGTCGGATTATACTAA ΤΤ ATTGTTG ATTG AT A ATCTTGT AGTTTGCTTTTCCT A ΑΤΤΤΑΤΤΤ ATCGT AGTCCTG ATTTGCCTCAGCTGTGCCTCACCCGTGCGATGGTCAATCAACTTGTTAGCCCAATCT GCTTAATCATGTACATTTGTTGTTAGAATCAGAGATCAAGCCAATTAGCTATCTTAT TGCTTATCTGTTCCATGTTCTGATCGATGTAACAGTCTACACTTTTGCTCTGTGCTAC TTGATTAAAACATTCTGACTTAAATTCATGATTGGAAGTTTCAGATCTGATTGTTGC CTTACTTGACTAATATCTATTCATGTGACACCTCTCTGTCTTGGTAACTTACCGCTGT TTGTTTGTAATTTCTGACTATGCAG (SEQ ID NO: 16)

In an embodiment, a promoter operably linked to a 5’-UTR and intron can be the Setaria italica ubiquitin 2 (Ubi2) promoter operably linked to a 5‘-UTR and intron. In one embodiment the promoter comprises or consists of the sequence of SEQ ID NO: 17:

TGCGTCTGGACGCACAAGTCATAGCATTATCGGCTAAAATTTCTTAATTTCTAAATTA GTCATATCGGCTAAGAAAGTGGGGAGCACTATCATTTCGTAGAACAAGAACAAGGT ATCATATATATATATATATATAATATTTAAACTTTGTTAAGTGGAATCAAAGTGCTAG TATTAATGGAGTTTCATGTGCATTAAATTTTATGTCACATCAGCAATTTTGTTGACTT GGCAAGGTCATTTAGGGTGTGTTTGGAAGACAGGGGCTATTAGGAGTATTAAACATA GTCT A ATT AC A A A ACT A ATTGC AC A ACCGCT A AGCTG AATCGC.G AG ATGGATCT ATT AAGCTTAATTAGTCCATGATTTGACAATGTGGTGCTACAATAACCATTTGCTAATGAT GG ATTACTT AGGTTTA ATAGATTCGTCTCGTGATTT AGCCTATGGGTTCTGCT ATT A A TTTTGTAATT AGCTCAT ΑΤΤΤ AGTTCTTATA ATTAGT ATCCG AACATCC AATGTGAC A TGCT A A AGTTT A ACCCTGGT ATCC A A ATG A AGTCTT ATG AG AGTTTC ATC ACTCCGGT

GA ATGTTT AG AT ACT AATTAG A AGT ATT A A ACGT AG ACTATTT ACA A AATCC ATT AC ATAAGACGAATCTAAACGGCGAGACGAATCTATTAAACCTAATTAGTCCATGATTTG ACAATGTGTTGCTACAGTAAACATTTGCTAATGATGGATTAATTAGGCTTAATAGATT CGTCTCGCCGTTTAGCCTCCACTTATGTAATGGGTTTTCTAAACAATCTACGTTTAAT ACTCCT A ATT AGT ATCT A A AT ATTC AATGTGAC ACGTGCT A A A A AT A AGTC AGTGG A AGGAAGAGAACGTCCCCTTAGTTTTCCATCTTATTAATTGTACGATGAAACTGTGCA GCCAGATGATTGACAATCGCAATACTTCAACTAGTGGGCCATGCACATCAGCGACGT GTAACGTCGTGAGTTGCTGTTCCCGTAGAGAAATATCAACTGGTGGGCCACGCACAT CAGCGTCGTGTAACGTGGACGGAGGAGCCCCGTGACGGCGTCGACATCGAACGGCC ATCTAACGGCTACCAGCAGGCGTACGGGTTGGAGTGGACTCCTTGCCTCTTTGCGCT GGCGGCTTCCGGAAATTGCGTGGCGGAGACGAGGCGGGCTCGTCTCACACGGCACG GAAGACGTCACGGGTTCCTTCCCCACCTCTCCTCTTCCCCACCGCCATAAATAGCCGA CCCCCTCGCCTTTCTCCCCAATCTCATCTCGTCTCGTGTTGTTCGGAGCACACCACCC GCCCCAAATCGTTCTTCCCGCAAGCCTCGGCGATCCTTCACCCGCTTCAAGGTACGGC G ATCGTCTTCCTCCTCT AG ATCGGCGTG ATCTGC A AGT AGTTGATTTGGT AG ATGGTT AGGATCTGTGCACTGAAGAAATCATGTTAGATCCGCGATGTTTCTGTTCGTAGATGG CTGGGAGGTGGAATTTTTGTGTAGATCTGATATGTTCTCCTGTTTATCTTGTCACGCT CCTGCG ATTTGTGGGG ΑΤΤΤΤ AGGTCGTTG ATCTGGG A ATCGTGGGGTTGCTTCT AGG CTGTTCGT AG ATG AGGTCGTTCTC ACGGTTT ACTGG ATC ATTGCCT AGT AG ATC AGCT CGGGCTTTCGTCTTTGTATATGGTGCCCATACTTGCATCTATGATCTGGTTCCGTGGT GTT ACCT AGGTTTCTGCGCCTG ATTCGTCCG ATCG ATTTTGTT A GC ATGTGGT A A ACG TTTGGTCATGGTCTGATTTAGATTAGAGTCGAATAGGATGATCTCGATCTAGCTCTTG GG ATT A AT ATGC ATGTGTC ACC A ATCTGTTCCGTGGTT A AG ATG ATG A ATCTATGCTT AGTTAATGGGTGTAGATATATATGCTGCTGTTCCTCAATGATGCCGTAGCTTTTACCT GAGCAGCATGGATCCTCCTGTTACTTAGGTAGATGCACATGCTTATACiATCAAGATA TGTACTGCTACTGTTGGAATTCTTTAGTATACCTGATGATCATCCATGCTCTTGTTACT TGTTTTGGT AT ACTTGGATGATGGC ATGCTGCTGCTTTTTGTTGATTTGAGCCC ATCC ATATCTGCATATGTCACATGATTAAGATGATTACGCTGTTTCTGTATGATGCCATAGC TTTTATGTGAGCAACATGCATCCTCCTGGTTATATGCATTAATAGATGGAAGATATCT ATTGCTACAATTTGATGATTATTTTGTACATACGATGATCAAGCATGCTCTTCATACT TTGTTGATATACTTGGATAATGAAATGCTGCTGCACGTTCATTCTATAGCACTAATGA TGTGATGAACACGCACGACCTGTTTGTGGCATCTGTTTGAATGTGTTGTTGCTGTTCA CT AG AG ACTGTTTT ATT A ACCT ACTGCT AG AT ACTT ACCCTTCTGTCTGTTT ATTCTTT TGCAG (SEQIDNO:17)

In an embodiment, a promoter operably linked to a 5’-UTR and intron can be the Panicum virgatum (Switchgrass) ubiquitin promoter operably linked to a 5’-UTR and intron. In one embodiment the promoter comprises or consists of the sequence of SEQ ID NO: 39:

TTGAATTTTAATTTCAAATTTTGCAGGGTAGTAGTGGACATCACAATACATATTTAG AAAAAGTTTTATAATTTTCCTCCGTTAGTTTTCATATAATTTTGAACTCCAACGATT AATCTATTATTAAATATCCCGATCTATCAAAATAATGATAAAAATTTATGATTAATT TTTCTAACATGTGTT ATGGTGTGT ACTATCGTCTT ΑΤΑ ΑΑ ATTTC A ACTTAAAACTC CACCTATACATGGAGAAATGAAAAAGACGAATTACAGTAGGGAGTAATTTGAACC AAATGGAATAGTTTGAGGGTAAAATGAACTAAACAATAGTTTAGGAGGTTATTCAG ATTTTAGTTATAGTTGAGAGGAGTAATTTAGACTTTTTCCTATCTTGAATTGTTGAC GGCTCTCCTATCGGATATCGGATGGAGTCTTTCAGCCCAACATAACTTCATTCGGGC CCAAACGTTCGTCCATCCAGCCTAGGGAGAACATTTTGCCCATGATATCTGTTTTTC TTTTTTTCT ATTTTC ACTGGTATT AT AGG AGGG A A AT AT AC A ACGTGTTC ACCTTTG GTTTCATTCTTGTTCCATCTGAATTTATCTAAAACTGTGTTTGAACTTCGTAAGAATT TTGTTCGATCTGTCCGGTACATCGTGTTGATAGGTGGCCTCCGAGATTCTTCTTTTT AACCGGCAAAGTAAAATAATCTCAGCTCCAGCCTAACGTCAATTATCAGAGAGAG A A A AAA AT ΑΤΤΤΤΤΤΤ ATG ATTG ATCGG A A ACC A ACCGCCTTACGTGTCGATCCTG GTTCCTGGCCGGCACGGCGGAGGAAAGCGACCGACCTCGCAACGCCGGCGCACGG CGCCGCCGTGTTGGACTTGGTCTCCCGCGACTCCGTGGGCCTCGGCTTATCGCCGCC GCTCCATCTCAACCGTCCGCTTGGACACGTGGAAGTTGATCCGTCGCGCACCAGCC TCGGAGGTAACCTAACTGCCCGTACTATAAATCCGGGATCCGGCCTCTCCAATCCC CATCGCCACAAGTTCGCGATCTCTCGATTTCACAAATCGCCGAGAAGACCCGAGCA TCTCTCCTCTATCACGTTGGTAATCTTCGAATGATCTGCTGCCTGGCTCGCTGTTCCC CCTCGTT ATGC ACTGTTTCC ATC ACG AGTTTTTTTTTTC ATC ATCT AATCT ATGCGGT TGCGGAAGAATTGTGGCTAGTGGAGTAGTTTTCTGTGCTTGATCGGTAGATTCGAT GTGTGGGTGTATGGATGTTTTCTGAAAAGTTGCTGGATTAGTTTACGCTTTCAGGCC GCAGGTCTGTTCGAAATTGATTATGAAGTCTATATGCTTTGGATCTATCGATTTCCA GTTTT ATTC AGATGT AGGCC A A A ΑΑ ATTGTCGGC ATTTGTGTGG A ATT AGTTGGCCT TTAGGTCTGCACATTCATGGTGACGGCACAGTTGCTGCTGGCTGTTGCGTGGGACG AGTTATTATAGTTGTTTTTGTTTTTCCCTGATTGATTCACATTTTCAATGATAACTAG CCTTTGTCACCTAACCAAGTCCAGGTTGATCCTATCTGTGTTCTTCAGCTACCAGTT TGCATAGATGATGGTGTATTCGATTGCTTTAGTAGGCCTTCTGATTTCAC ATCTAAT TCTGTC ATG A ΑΤΑΤ AG AT A ACTTT AC ATGCTTTTG ΑΤΑΤ ACTTTAT ATTTCiA ACTGTT CACTGTCCAGCCTATTTTGGATAATTGAGTGCATTGGCTTTTGATGCCTGAATTATT CACATGTTCCTGGATAATTGACCTGTGTCACCTAGTTGACTGTTTTTTGAGGTGCCA CCCGTCTGTTCAGCTGATTTGTGTATTCGATTGCTCTAGTTAATCTTTTGATTATGCA GCTAGTGCTTTGTCATATGTAGCTTTATAGGCTTCTGATGTCCTTGGATATAGTTCA GTCTACTTGTCAAGTTGCTTTACAAGTAGTAGCTCTGATTCTATTTCiGCTTCCTGAG TCAGAGCTTTGCAAATTGCTTGTTGTTACATTACATCATATTACTTGAATTGCAGTT ATTTAATGGTTGGATTGTTGCTGTTTACTTCTACATTTTTTGCTGTTTTATATTATAC TAAAATGTTTGTGTTGCTGCTTTTCAG (SEQ ID ΝΟ:39)

In an embodiment, a nucleic acid construct is provided comprising a promoter operably linked to an intron and 5’-UTR. In one embodiment the construct comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID ΝΟ:39. In one embodiment, a nucleic acid construct is provided comprising a ubiquitin promoter sequence comprising or consisting of a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID ΝΟ:39 operably linked to a polylinker. Optionally, the construct can further comprise 3’UTR that is operably linked to the 3’ end of the polylinker. In an embodiment, a gene expression cassette is provided comprising a ubiquitin promoter sequence wherein the promoter sequence comprises or consists of a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:15, SEQ ID ΝΟ:16, SEQ ID NO: 17, or SEQ ID ΝΟ:39. operably linked to a non-ubiquitin transgene. Optionally, the construct can further comprise 3’-UTR that is operably linked to the 3' end of the non-ubiquitin transgene.

In one embodiment the 3’-UTR sequence consists of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36. In an illustrative embodiment, the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In one embodiment the transgene is an herbicide resistance gene. In one embodiment a vector is provided comprising 1, 2, 3 or 4 promoter sequences independently selected from the group consisting of SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36,

In an embodiment, a gene expression cassette comprises a ubiquitin promoter, a ubiquitin 5’-UTR, a ubiquitin intron, and a ubiquitin 3’-UTR. In an embodiment, a ubiquitin promoter, a ubiquitin 5’-UTR, a ubiquitin intron, and a ubiquitin 3’-UTR can each be independently a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter; Panicum virgatum Brachypodium distachyon or Setaria italica ubiquitin 5’-UTR; Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin intron; and, a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 3’-UTR. In an embodiment, a gene expression cassette comprises: a) a promoter, wherein the promoter is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:36; b) a 3’-UTR, wherein the 3’-UTR is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:37; c) a 5’ -UTR, wherein the 5’ -UTR is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID ΝΟ:14, or SEQ ID ΝΟ:38; or, d) an intron, wherein the intron is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID ΝΟ:39.

For example, a gene expression cassette may include both a promoter, an intron, and a 5’ UTR wherein the promoter is a polynucleotide of SEQ ID NO: 1, the intron is a polynucleotide of SEQ ID ΝΟ:7, and the 5’ -UTR is a polynucleotide of SEQ ID NO: 11. Likewise, a gene expression cassette may include both a promoter, an intron, and a 5’ -UTR wherein the promoter is a polynucleotide of SEQ ID ΝΟ:2, the intron is a polynucleotide of SEQ ID NO:8, and the 5’ UTR is a polynucleotide of SEQ ID NO: 12. Furthermore, a gene expression cassette may include both a promoter, an intron, and a 5’ -UTR wherein the promoter is a polynucleotide of SEQ ED ΝΟ:3, the intron is a polynucleotide of SEQ ID ΝΟ:9 and/or SEQ ID NO: 10, and the 5’ -UTR is a polynucleotide of SEQ ID NO: 13. In addition, a gene expression cassette may include both a promoter, an intron, and a 5’ -UTR wherein the promoter is a polynucleotide of SEQ ID NO: 35, the intron is a polynucleotide of SEQ ED ΝΟ:37, and the 5’ -UTR is a polynucleotide of SEQ ID ΝΟ:38.

For example, a gene expression cassette may include both a promoter, an intron, a 5’ UTR, and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID NOT, the intron is a polynucleotide of SEQ ID ΝΟ:7, the 5’ -UTR is a polynucleotide of SEQ ID NO: 11, and the 3’UTR is a polynucleotide of SEQ ID ΝΟ:4. Likewise, a gene expression cassette may include both a promoter, an intron, a 5’ -UTR, and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID ΝΟ:2, the intron is a polynucleotide of SEQ ID ΝΟ:8, the 5’ -UTR is a polynucleotide of SEQ ID NO: 12, and the 3’-UTR is a polynucleotide of SEQ ID ΝΟ:5. Furtheimore, a gene expression cassette may include both a promoter, an intron, a 5’ -UTR, and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID ΝΟ:3, the intron is a polynucleotide of SEQ ID ΝΟ:9 and/or SEQ ID NO: 10, the 5’ -UTR is a polynucleotide of SEQ ID NO: 13 or 14, and the 3’-UTR is a polynucleotide of SEQ ID ΝΟ:6. In addition, a gene expression cassette may include both a promoter, an intron, a 5’ -UTR, and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID ΝΟ:35, the intron is a polynucleotide of SEQ ID ΝΟ:37, the 5’ -UTR is a polynucleotide of SEQ ID ΝΟ:38, and the 3’-UTR is a polynucleotide of SEQ ID ΝΟ:36.

In addition, a gene expression cassette may include both a promoter, and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID ΝΟ:1 and a 3^!-UTR of SEQ ID ΝΟ:6. hi an embodiment, a gene expression cassette may include both a promoter and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID NO: 1 and a 3’-UTR of SEQ ID ΝΟ:5. In an embodiment, a gene expression cassette may include both a promoter and a 3’-UTR wherein the promoter is a polynucleotide of SEQ ID NO: 1 and a 3’-UTR of SEQ ID ΝΟ:4. In an embodiment, a gene expression cassette may include both a promoter and a 3’ -UTR wherein the promoter is a polynucleotide of SEQ ID ΝΟ:35 and a 3’ -UTR of SEQ ID ΝΟ:36.

In an embodiment, a gene expression cassette comprises a ubiquitin promoter, ubiquitin 5’

-UTR, and a ubiquitin 3’-UTR that are operably linked to a non-ubiquitin transgene. In an embodiment, a gene expression cassette comprises a ubiquitin promoter, a ubiquitin intron, ubiquitin 5’ -UTR, and a ubiquitin 3’-UTR that are operably linked to a non-ubiquitin transgene.

A promoter, an intron, a 5’ -UTR, and 3’-UTR can be operably linked to different transgenes within a gene expression cassette when a gene expression cassette includes one or more transgenes. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin promoter that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water use efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin promoter, an intron, and a 5’ -UTR that are operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water use efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin 3’-UTR that is operably linked to a transgene, wherein the transgene encodes for a gene product that enhances insecticidal resistance, herbicide tolerance, nitrogen use efficiency, water us efficiency, nutritional quality or combinations thereof.

A ubiquitin intron and a 5’ -UTR can be operably linked to different promoters within a gene expression cassette. In an illustrative embodiment, the promoters originate from a plant (e.g., Zea mays ubiquitin 1 promoter), a virus (e.g., Cassava vein mosaic virus promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an illustrative embodiment, a gene expression cassette comprises a ubiquitin promoter that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water use efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In an embodiment, a vector comprises a gene expression cassette as disclosed herein. In an embodiment, a vector can be a plasmid, a cosmid, a bacterial artificial chromosome (BAC), a bacteriophage, a virus, or an excised polynucleotide fragment for use in direct transformation or gene targeting such as a donor DNA.

In accordance with one embodiment a nucleic acid vector is provided comprising a recombinant gene cassette wherein the recombinant gene cassette comprises a ubiquitin based promoter operably linked to a polylinker sequence, a non-ubiquitin transgene or combination thereof. In one embodiment the recombinant gene cassette comprises a ubiquitin based promoter operably linked to a non-ubiquitin transgene. In one embodiment the recombinant gene cassette comprises a ubiquitin based promoter as disclosed herein operably linked to a polylinker sequence. The polylinker is operably linked to the ubiquitin based promoter in a manner such that insertion of a coding sequence into one of the restriction sites of the polylinker will operably link the coding sequence allowing for expression of the coding sequence when the vector is transfected into a host cell.

In accordance with one embodiment the ubiquitin based promoter comprises SEQ ID NO:

1 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 1. In accordance with one embodiment the promoter sequence has a total length of no more than 1.5, 2, 2.5, 3 or 4 kb. In accordance with one embodiment the ubiquitin based promoter consists of SEQ ID NO: 1 or a 1029 bp sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 1.

In accordance with one embodiment a nucleic acid vector is provided comprising a gene cassette that consists of SEQ ID NO: 15, a non-ubiquitin transgene and a 3'-UTR, wherein SEQ ID NO: 15 is operably linked to the 5’ end of the non-ubiquitin transgene and the 3'-UTR is operably linked to the 3' end of the non-ubiquitin transgene. In a further embodiment the 3' untranslated sequence comprises SEQ ID NO: 4 or a sequence that has 90, 95, 99 or 100% sequence identity with SEQ ID NO: 4. In accordance with one embodiment a nucleic acid vector is provided comprising a gene cassette that consists of SEQ ID NO: 15, or a 2077 bp sequence that has 90, 95, or 99% sequence identity with SEQ ID NO: 15, a non-ubiquitin transgene and a 3-UTR, wherein SEQ ID NO: 15 is operably linked to the 5' end of the non-ubiquitin transgene and the 3'-UTR is operably linked to the 3' end of the non-ubiquitin transgene. In a further embodiment the 3' untranslated sequence comprises SEQ ID NO: 4 or a sequence that has 90, 95, 99 or 100% sequence identity with SEQ ID NO: 4. Ia further embodiment the 3' untranslated sequence consists of SEQ ID NO: 4,or a 1026 bp sequence that has 90, 95, or 99% sequence identity with SEQ ID NO: 4.

In accordance with one embodiment the nucleic acid vector further comprises a sequence encoding a selectable maker. In accordance with one embodiment the recombinant gene cassette is operably linked to an AgiObacterium T-DNA border. In accordance with one embodiment the recombinant gene cassette further comprises a first and second T-DNA border, wherein first Τ-DNA border is operably linked to one end of the gene construct, and said second T-DNA border is operably linked to the other end of the gene construct. The first and second Agrobacterium Τ-DNA borders can be independently selected from T-DNA border sequences originating from bacterial strains selected from the group consisting of a nopaline synthesizing Agrobacterium Τ-DNA border, an ocotopine synthesizing Agrobacterium T-DNA border, a succinamopine synthesizing Agrobacterium T-DNA border, or any combination thereof. In one embodiment an Agrobacterium strain selected from the group consisting of a nopaline synthesizing strain, a mannopine synthesizing strain, a succinamopine synthesizing strain, or an octopine synthesizing strain is provided, wherein said strain comprises a plasmid wherein the plasmid comprises a transgene operably linked to a sequence selected from SEQ ID NO: 1, SEQ ID NO: 15 or a sequence having 90, 95, or 99% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 15.

Transgenes of interest and suitable for use in the present disclosed constructs include, but are not limited to, coding sequences that confer (1) resistance to pests or disease, (2) resistance to herbicides, and (3) value added traits as disclosed in WO2013116700 (DGT-28), US20110107455 (DSM-2), U.S. Pat. Nos. 8,283,522 (AAD-12); 7,838,733 (AAD-1); 5,188,960; 5,691,308;

6,096,708; and 6,573,240 (CrylF); U.S. Pat. Nos. 6,114,138; 5,710,020; and 6,251,656 (CrylAc);

U.S. Pat. Nos. 6,127,180; 6,624,145 and 6,340,593 (Cry34Abl); U.S. Pat. Nos. 6,083,499;

6,548,291 and 6,340,593 (Cry35Abl), the disclosures of which are incorporated herein. In accordance with one embodiment the transgene encodes a selectable marker or a gene product conferring insecticidal resistance, herbicide tolerance, nitrogen use efficiency, water use efficiency, or nutritional quality.

In accordance with one embodiment a nucleic acid vector is provided comprising a gene cassette wherein the gene cassette comprises a promoter region operably linked to the 5' end of a transgene wherein the 3' end of the transgene is linked to a 3' untranslated region. In one embodiment the promoter region comprises SEQ ID NO: 1 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 1. In accordance with one embodiment the promoter region consists of SEQ ID NO: 1 or SEQ ID NO: 15. In one embodiment the 3' untranslated sequence comprises SEQ ED NO: 4 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 4, and in one embodiment the 3' untranslated sequence consists of SEQ ID NO: 4 or a 1026 bp sequence having 90, 95 or 99% sequence identity with SEQ ID NO: 4.

In accordance with one embodiment a nucleic acid vector is provided comprising a gene cassette wherein the gene cassette comprises a promoter region operably linked to the 5' end of a 5' untranslated sequence, wherein the 3’ end of the 5' untranslated sequence is operably linked to the 5' end of the transgene wherein the 3' end of the transgene is linked to a 3' untranslated region.

In one embodiment the promoter region comprises or consists of SEQ ID NO: 1 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 1. In one embodiment the promoter region consists of SEQ ID NO: 1 or a 1029 bp sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 1. In accordance with one embodiment the 5' untranslated sequence comprises or consists of SEQ ID NO: 11 or a sequence that has 90% sequence identity with SEQ ID NO: 11. In accordance with one embodiment the 5' untranslated sequence consists of SEQ ID NO: 11 or a 55 bp sequence that has 90% sequence identity with SEQ ED NO: 11. In one embodiment the 3' untranslated sequence comprises or consists of SEQ ID NO: 4 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 4. In one embodiment the 3' untranslated sequence consists of SEQ ID NO: 4 or a 1026 bp sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 4. In a further embodiment the nucleic acid vector further comprises a ubiquitin intron inserted between the 5' untranslated region and the transgene, and operably linked to the promoter and transgene. In one embodiment the ubiquitin intron comprises or consists of SEQ ID NO: 7 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 7. hi one embodiment the ubiquitin intron consists of SEQ ID NO: 7 or a 993 bp sequence that has 90, 95 or 99% sequence identity with SEQ ED NO: 7.

In accordance with one embodiment a nucleic acid vector is provided comprising a gene cassette wherein the gene cassette comprises a promoter region operably linked to the 5' end of a transgene wherein the 3' end of the transgene is linked to a 3’ untranslated region. In one embodiment the promoter region comprises SEQ ID NO: 40 or a sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 40.

CTGCTCGTTCAGCCCACAGTAACACGCCGTGCGACATGCAGATGCCCTCCACCACG CCGACCAACCCCAAGTCCGCCGCGCTCGTCCACGGCGCCATCCGCATCCGCGCGTC AACGTCATCCGGAGGAGGCGAGCGCGATGTCGACGGCCACGGCGGCGGCGGACAC GACGGCGACGCCCCGACTCCGCGCGCGCGTCAAGGCTGCAGTGGCGTCGTGGTGGC CGTCCGCCTGCACGAGATCCCCGCGTGGACGAGCGCCGCCTCCACCCAGCCCCTAT ATCGAGAAATCAACGGTGGGCTCGAGCTCCTCAGCAACCTCCCCACCCCCCCTTCC GACCACGCTCCCTTCCCCCGTGCCCCTCTTCTCCGTAAACCCGAGCCGCCGAGAAC AAC ACCAACG A A AGGGCG A AG AG A ATCGCCATAG AG AGG AG ATGGGCGG AGGCG GATAGTTTCAGCCATTCACGGAGAAATGGGGAGGAGAGAACACGACATCATACGG ACGCGACCCTCTAGCTGGCTGGCTGTCCTAAAGAATCGAACGGAATCGCTGCGCCA GGAGAAAACGAACGGTCCTGAAGCATGTGCGCCCGGTTCTTCCAAAACACTTATCT TTAAGATTGAAGTAGTATATATGACTGAAATTTTTACAAGGTTTTTCCCCATAAAAC AGGTG AGCTTATCTCATCCTTTTGTTTAGGATGTACGTATTATATATGACTGAATAT

GTACCTTTGTGCCGTGTATATGGACTAGAGCCATCGGGACGTTTCCGGAGACTGCG TGGTGGGGGCGATGGACGCACAACGACCGCATTTTCGGTTGCCGACTCGCCGTTCG CATCTGGTAGGCACGACTCGTCGGGTTCGGCTCTTGCGTGAGCCGTGACGTAACAG ACCCGTTCTCTTCCCCCGTCTGGCCATCCATAAATCCCCCCTCCATCGGCTTCCCTTT CCTCAATCCAGCACCCTGATTCCGATCGAAAAGTCCCCGCAAGAGCAAGCGACCGA TCTCGTGAATCTCCGTCAAG (SEQ ID NO: 40)

In accordance with one embodiment the promoter region consists of SEQ ID NO: 40 or a 1084 bp sequence having 90, 95 or 99% sequence identity with SEQ ID NO: 40. In accordance with one embodiment the promoter region consists of SEQ ID NO: 40. In one embodiment the 3' untranslated sequence consists of SEQ ID NO: 4 or a 1026 bp sequence that has 90, 95 or 99% sequence identity with SEQ ID NO: 4, and in one embodiment the 3’ untranslated sequence consists of SEQ ID NO: 4.

In an embodiment, a cell or plant is provided comprising a gene expression cassette as disclosed herein. In an embodiment, a cell or plant comprises a vector comprising a gene expression cassette as disclosed herein. In an embodiment, a vector can be a plasmid, a cosmid, a bacterial artificial chromosome (BAC), a bacteriophage, or a virus. Thereby, a cell or plant comprising a gene expression cassette as disclosed herein is a transgenic cell or transgenic plant, respectively. In an embodiment, a transgenic plant can be a monocotyledonous plant. In an embodiment, a transgenic monocotyledonous plant can be, but is not limited to maize, wheat, rice, sorghum, oats, rye, bananas, sugar cane, and millet. In an embodiment, a transgenic plant can be a dicotyledonous plant. In an embodiment, a transgenic dicotyledonous plant can be, but is not limited to soybean, cotton, sunflower, and canola. An embodiment also includes a transgenic seed from a transgenic plant as disclosed herein.

In an embodiment, a gene expression cassette includes two or more transgenes. The two or more transgenes may not be operably linked to the same promoter, intron, or 5’-UTR or 3’UTR as disclosed herein. In an embodiment, a gene expression cassette includes one or more transgenes. In an embodiment with one or more transgenes, at least one transgene is operably linked to a promoter, intron, 5’-UTR, or 3’-UTR or the subject disclosure.

Various selectable markers also described as reporter genes can be incorporated into a chosen expression vector to allow for identification and selectable of transformed plants (“transformants”). Many methods are available to confimi expression of selectable markers in transformed plants, including for example DNA sequencing and PCR (polymerase chain reaction), Southern blotting, RNA blotting, immunological methods for detection of a protein expressed from the vector, e g., precipitated protein that mediates phosphinothricin resistance, or visual observation of other proteins such as reporter genes encoding β-glucuronidase (GUS), luciferase, green fluorescent protein (GFP), yellow fluorescent protein (YEP), DsRed, βgalactosidase, chloramphenicol acetyltransferase (CAT), alkaline phosphatase, and the like (See Sambrook, et αℓ., Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Press, Ν.Υ., 2001, the content of which is incorporated herein by reference in its entirety).

Selectable marker genes are utilized for selection of transformed cells or tissues.

Selectable marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (ΝΕΟ) and hygromycin phosphotransferase (HPT) as well as genes conferring resistance to herbicidal compounds. Herbicide resistance genes generally code for a modified target protein insensitive to the herbicide or for an enzyme that degrades or detoxifies the herbicide in the plant before it can act. For example, resistance to glyphosate has been obtained by using genes coding for mutant target enzymes, 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS). Genes and mutants for EPSPS are well known, and further described below. Resistance to glufosinate ammonium, bromoxynil, and 2,4-dichlorophenoxyacetate (2,4-D) have been obtained by using bacterial genes encoding pat or DSM-2, a nitrilase, an aad-1, or an aad-12 gene, which detoxifies the respective herbicides.

In an embodiment, herbicides can inhibit the growing point or meristem, including imidazolinone or sulfonylurea, and genes for resistance/tolerance of acetohydroxyacid synthase (AHAS) and acetolactate synthase (ALS) for these herbicides are well known. Glyphosate resistance genes include mutant 5-enolpyruvylshikimate-3-phosphate synthase (EPSPs) and clgt-28 genes (via the introduction of recombinant nucleic acids and/or various forms of in vivo mutagenesis of native EPSPs genes), aroA genes and glyphosate acetyl transferase (GAT) genes, respectively). Resistance genes for other phosphono compounds include bar genes from Streptomyces species, including Streptomyces hygroscopicus and Streptomyc.es viridichromogenes, and pyridinoxy or phenoxy proprionic acids and cyclohexones (ACCase inhibitor-encoding genes). Exemplary genes conferring resistance to cyclohexanediones and/or aryloxyphenoxypropanoic acid (including Haloxyfop, Diclofop, Fenoxyprop, Fluazifop, Quizalofop) include genes of acetyl coenzyme A carboxylase (ACCase)-Accl-SI, Accl-S2 and Accl-S3. In an embodiment, herbicides can inhibit photosynthesis, including triazine (psbA and ls+ genes) or benzonitrile (nitrilase gene).

In an embodiment, selectable marker genes include, but are not limited to genes encoding: neomycin phosphotransferase Π; cyanamide hydratase; aspartate kinase;

dihydrodipicolinate synthase; tryptophan decarboxylase; dihydrodipicolinate synthase and desensitized aspartate kinase; bar gene; tryptophan decarboxylase; neomycin phosphotransferase (ΝΕΟ); hygromycin phosphotransferase (HPT or HYG); dihydrofolate reductase (DHFR); phosphinothricin acetyltransferase; 2,2-dichloropropionic acid dehalogenase; acetohydroxyacid synthase; 5-enolpyruvyl-shikimate-phosphate synthase (aroA);

haloarylnitrilase; acetyl-coenzyme A carboxylase; dihydropteroate synthase (sul I); and 32 kD photosystem II polypeptide (psbA).

An embodiment also includes genes encoding resistance to: chloramphenicol;

methotrexate; hygromycin; spectinomycin; bromoxynil; glyphosate; and phosphinothricin.

The above list of selectable marker genes is not meant to be limiting. Any reporter or selectable marker gene are encompassed by the present invention.

Selectable marker genes are synthesized for optimal expression in a plant. For example, in an embodiment, a coding sequence of a gene has been modified by codon optimization to enhance expression in plants. A selectable marker gene can be optimized for expression in a particular plant species or alternatively can be modified for optimal expression in dicotyledonous or monocotyledonous plants. Plant preferred codons may be determined from the codons of highest frequency in the proteins expressed in the largest amount in the particular plant species of interest. In an embodiment, a selectable marker gene is designed to be expressed in plants at a higher level resulting in higher transformation efficiency. Methods for plant optimization of genes are well known. Guidance regarding the optimization and production of synthetic DNA sequences can be found in, for example, WO2013016546, WO2011146524, WO1997013402, US Patent No. 6166302, and US Patent No. 5380831, herein incorporated by reference.

Suitable methods for transformation of plants include any method by which DNA can be introduced into a cell, for example and without limitation: electroporation (see, e.g., U.S. Patent 5,384,253); micro-projectile bombardment (see, e.g., U.S. Patents 5,015,580, 5,550,318, 5,538,880,6,160,208, 6,399,861, and 6,403,865); Agrobacterium-mediated transformation (see, e.g., U.S. Patents 5,635,055, 5,824,877, 5,591,616; 5,981,840, and 6,384,301); and protoplast transformation (see, e.g., U.S. Patent 5,508,184).

A DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as agitation with silicon carbide fibers (See, e.g., U.S. Patents 5,302,523 and 5,464,765), or the DNA constructs can be introduced directly to plant tissue using biolistic methods, such as DNA particle bombardment (see, e.g., Klein et al. (1987) Nature 327:70-73).

Alternatively, the DNA construct can be introduced into the plant cell via nanoparticle transformation (see, e.g., US Patent Publication No. 20090104700, which is incorporated herein by reference in its entirety).

In addition, gene transfer may be achieved using non-Agrobacterium bacteria or viruses such as Rhizobium sp. NGR234, Sinorhizoboium meliloti, Mesorhizobium loti, potato vims X, cauliflower mosaic vims and cassava vein mosaic vims and/or tobacco mosaic vims, See, e.g., Chung et al. (2006) Trends Plant Sci. 11(1): 1-4.

Through the application of transformation techniques, cells of virtually any plant species may be stably transformed, and these cells may be developed into transgenic plants by well-known techniques. For example, techniques that may be particularly useful in the context of cotton transformation are described in U.S. Patents 5,846,797, 5,159,135, 5,004,863, and 6,624,344;

techniques for transforming Brcissicci plants in particular are described, for example, in U.S. Patent 5,750,871; techniques for transforming soy bean are described, for example, in U.S. Patent 6,384,301 ; and techniques for transforming maize are described, for example, in U.S. Patents 7,060,876 and 5,591,616, and International PCT Publication WO 95/06722.

After effecting delivery of an exogenous nucleic acid to a recipient cell, a transformed cell is generally identified for further culturing and plant regeneration. In order to improve the ability to identify transformants, one may desire to employ a selectable marker gene with the transformation vector used to generate the transformant. In an illustrative embodiment, a transformed cell population can be assayed by exposing the cells to a selective agent or agents, or the cells can be screened for the desired marker gene trait.

Cells that survive exposure to a selective agent, or cells that have been scored positive in a screening assay, may be cultured in media that supports regeneration of plants. In an embodiment, any suitable plant tissue culture media may be modified by including further substances, such as growth regulators. Tissue may be maintained on a basic media with growth regulators until sufficient tissue is available to begin plant regeneration efforts, or following repeated rounds of manual selection, until the morphology of the tissue is suitable for regeneration (e.g., at least 2 weeks), then transferred to media conducive to shoot formation. Cultures are transferred periodically until sufficient shoot formation has occurred. Once shoots are formed, they are transferred to media conducive to root formation. Once sufficient roots are formed, plants can be transferred to soil for further growth and maturity.

To confirm the presence of a desired nucleic acid comprising constructs provided in regenerating plants, a variety of assays may be performed. Such assays may include: molecular biological assays, such as Southern and northern blotting and PCR; biochemical assays, such as detecting the presence of a protein product, e.g., by immunological means (ELISA, western blots, and/or LC-MS MS spectrophotometry) or by enzymatic function; plant part assays, such as leaf or root assays; and/or analysis of the phenotype of the whole regenerated plant.

Transgenic events may be screened, for example, by PCR amplification using, e.g., oligonucleotide primers specific for nucleic acid molecules of interest. PCR genotyping is understood to include, but not be limited to, polymerase-chain reaction (PCR) amplification of genomic DNA derived from isolated host plant callus tissue predicted to contain a nucleic acid molecule of interest integrated into the genome, followed by standard cloning and sequence analysis of PCR amplification products. Methods of PCR genotyping have been well described {see, e.g., Rios et αℓ. (2002) Plant J. 32:243-53), and may be applied to genomic DNA derived from any plant species or tissue type, including cell cultures. Combinations of oligonucleotide primers that bind to both target sequence and introduced sequence may be used sequentially or multiplexed in PCR amplification reactions. Oligonucleotide primers designed to anneal to the target site, introduced nucleic acid sequences, and/or combinations of the two may be produced.

Thus, PCR genotyping strategies may include, for example and without limitation: amplification of specific sequences in the plant genome; amplification of multiple specific sequences in the plant genome; amplification of non-specific sequences in the plant genome; and combinations of any of the foregoing. One skilled in the ait may devise additional combinations of primers and amplification reactions to interrogate the genome. For example, a set of forward and reverse oligonucleotide primers may be designed to anneal to nucleic acid sequence(s) specific for the target outside the boundaries of the introduced nucleic acid sequence.

Forward and reverse oligonucleotide primers may be designed to anneal specifically to an introduced nucleic acid molecule, for example, at a sequence corresponding to a coding region within a nucleotide sequence of interest comprised therein, or other parts of the nucleic acid molecule. Primers may be used in conjunction with primers described herein. Oligonucleotide primers may be synthesized according to a desired sequence and are commercially available (e.g., from Integrated DNA Technologies, Inc., Coralville, IA). Amplification may be followed by cloning and sequencing, or by direct sequence analysis of amplification products. In an embodiment, oligonucleotide primers specific for the gene target are employed in PCR amplifications.

In an embodiment, a method of expressing at least one transgene in a plant comprises growing a plant comprising a ubiquitin promoter operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprising growing a plant comprising a ubiquitin 5’-UTR operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprising growing a plant comprising a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprising growing a plant comprising a ubiquitin promoter, a ubiquitin 5’ -UTR, and a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprising growing a plant comprising a ubiquitin 3’-UTR operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprising culturing a plant tissue or plant cell comprising a ubiquitin promoter operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprising culturing a plant tissue or plant cell comprising a ubiquitin 5’-UTR operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprising culturing a plant tissue or plant cell comprising a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprising culturing a plant tissue or plant cell comprising a ubiquitin promoter, a ubiquitin 5’

-UTR, and a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprising culturing a plant tissue or plant cell comprising a ubiquitin 3’-UTR operably linked to at least one transgene.

In an embodiment, a method of expressing at least one transgene in a plant comprises growing a plant comprising a gene expression cassette comprising a ubiquitin promoter operably linked to at least one transgene. In one embodiment the ubiquitin promoter consists of a sequence selected from SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, SEQ ID ΝΟ:35, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID ΝΟ:39 or a sequence that has 90, 95 or 995 sequence identity with a sequence selected from SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, SEQ ID ΝΟ:35, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID ΝΟ:39.

In an embodiment, a method of expressing at least one transgene in a plant comprises growing a plant comprising a gene expression cassette comprising a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprises growing a plant comprising a gene expression cassette comprising a ubiquitin 5’ UTR operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprises growing a plant comprising a gene expression cassette comprising a ubiquitin promoter, a ubiquitin 5’ -UTR, and a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant comprises growing a plant comprising a gene expression cassette comprising a ubiquitin 3’-UTR operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprises culturing a plant tissue or plant cell comprising a gene expression cassette a ubiquitin promoter operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprises culturing a plant tissue or plant cell comprising a gene expression cassette a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprises culturing a plant tissue or plant cell comprising a gene expression cassette a ubiquitin 5’ -UTR operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprises culturing a plant tissue or plant cell comprising a gene expression cassette a ubiquitin promoter, a ubiquitin 5’ -UTR, and a ubiquitin intron operably linked to at least one transgene. In an embodiment, a method of expressing at least one transgene in a plant tissue or plant cell comprises culturing a plant tissue or plant cell comprising a gene expression cassette comprising a ubiquitin 3’-UTR operably linked to at least one transgene.

In an embodiment, a plant, plant tissue, or plant cell comprises a ubiquitin promoter. In an embodiment, a ubiquitin promoter can be a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter. In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprises a promoter, wherein the promoter is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3 or SEQ ID ΝΟ:35 wherein the promoter is operably linked to a non-ubiquitin transgene. In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a sequence selected from SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, SEQ ID ΝΟ:35, SEQ ID ΝΟ:15, SEQ ID ΝΟ:16, SEQ ID ΝΟ:17, and SEQ ID ΝΟ:39 or a sequence that has 90, 95 or 995 sequence identity with a sequence selected from SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, SEQ ID ΝΟ:35, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID ΝΟ:39 that is operably linked to a non-ubiquitin transgene. In an illustrative embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a ubiquitin promoter that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a 3’-UTR. In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a ubiquitin 3’-UTR. In an embodiment, the ubiquitin 3’-UTR is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin 3’-UTR. hi an embodiment, a 3’-UTR can be the Brachypodium distachyon ubiquitinl C (UbilC) 3’-UTR, Brachypodium distachyon ubiquitinl 3’-UTR, or Setaria italica ubiquitin 3’-UTR.

In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising an intron, wherein the intron is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:7, SEQ ID ΝΟ:8, SEQ ID ΝΟ:9, SEQ ID NO: 10, or SEQ ID ΝΟ:37. In an embodiment, a gene expression cassette comprises a ubiquitin intron that is operably linked to a promoter, wherein the promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter, or a promoter that originates from a plant (e.g., /℮α mays ubiquitin 1 promoter), a virus (e.g., Cassava vein mosaic vims promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a ubiquitin intron that is operably linked to a transgene. In an illustrative embodiment, a plant, plant tissue, or plant cell comprising a gene expression cassette comprising a ubiquitin intron that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a 5’-UTR, wherein the 5’-UTR is at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID ΝΟ:38. In an embodiment, a gene expression cassette comprises a ubiquitin intron that is operably linked to a promoter, wherein the promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter, or a promoter that originates from a plant (e.g., Zea mays ubiquitin 1 promoter), a virus (e.g., Cassava vein mosaic virus promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a ubiquitin 5’-UTR that is operably linked to a transgene. In an illustrative embodiment, a plant, plant tissue, or plant cell comprising a gene expression cassette comprising a ubiquitin 5’-UTR that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a ubiquitin promoter and a ubiquitin 3’-UTR. In an embodiment, a plant, plant tissue, or plant cell comprises a ubiquitin promoter and 3’-UTR can each be independently a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter and a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter. In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a) a promoter, wherein the promoter is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35 and b) a 3MJTR. wherein the 3’-UTR is at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, or 100% identical to SEQ ID ΝΟ:4, SEQ ID ΝΟ:5, SEQ ID ΝΟ:6, or SEQ ID ΝΟ:36.

In an embodiment, a plant, plant tissue, or plant cell comprises a gene expression cassette comprising a ubiquitin promoter, ubiquitin 5'-UTR. ubiquitin intron, and a ubiquitin 3'-UTR that are operably linked to a transgene. The promoter, intron, 5’ -UTR, and 3’-UTR can be operably linked to different transgenes within a gene expression cassette when a gene expression cassette includes two or more transgenes. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin promoter that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In an illustrative embodiment, a gene expression cassette comprises a ubiquitin intron that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In an embodiment, a gene expression cassette comprises a ubiquitin intron that is operably linked to a promoter, wherein the promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter, or a promoter that originates from a plant (e.g., Zea mays ubiquitin 1 promoter), a virus (e.g., Cassava vein mosaic virus promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an illustrative embodiment, a gene expression cassette comprises a ubiquitin 5’ -UTR that is operably linked to a transgene, wherein the transgene can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof. In an embodiment, a gene expression cassette comprises a ubiquitin 5’ -UTR that is operably linked to a promoter, wherein the promoter is a Panicum virgatum, Brachypodium distachyon or Setaria italica ubiquitin promoter, or a promoter that originates from a plant (e.g., Zea mays ubiquitin 1 promoter), a virus (e.g., Cassava vein mosaic vims promoter) or a bacteria (e.g., Agrobacterium tumefaciens delta mas). In an illustrative embodiment, a gene expression cassette comprises a ubiquitin 3’-UTR that is operably linked to a transgene, wherein the 3’-UTR can be an insecticidal resistance transgene, an herbicide tolerance transgene, a nitrogen use efficiency transgene, a water us efficiency transgene, a nutritional quality transgene, a DNA binding transgene, a selectable marker transgene, or combinations thereof.

In an embodiment, a plant, plant tissue, or plant cell comprises a vector comprising a ubiquitin promoter, 5’-UTR, intron, and/or 3’-UTR as disclosed herein. In an embodiment, a plant, plant tissue, or plant cell comprises a vector comprising a ubiquitin promoter, 5’-UTR, intron, and/or 3’-UTR as disclosed herein operably linked to a non-ubiquitin transgene. In an embodiment, a plant, plant tissue, or plant cell comprises a vector comprising a gene expression cassette as disclosed herein. In an embodiment, a vector can be a plasmid, a cosmid, a bacterial artificial chromosome (BAC), a bacteriophage, or a vims.

In accordance with one embodiment a plant, plant tissue, or plant cell is provided wherein the plant, plant tissue, or plant cell comprises a non-endogenous ubiquitin derived promoter sequence operably linked to a transgene, wherein the ubiquitin derived promoter sequence comprises a sequence SEQ ID NO: 1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35 or a sequence having 90. 95, 98 or 99% sequence identity with SEQ ID ΝΟ:1, SEQ ID ΝΟ:2, SEQ ID ΝΟ:3, or SEQ ID ΝΟ:35. In one embodiment a plant, plant tissue, or plant cell is provided wherein the plant, plant tissue, or plant cell comprises SEQ ID NO: 1, or a sequence that has 90% sequence identity with SEQ ID NO: 1 operably linked to a non-ubiquitin transgene. In one embodiment the plant, plant tissue, or plant cell is a dicotyledonous or monocotyledonous plant or a cell or tissue derived from a dicotyledonous or monocotyledonous plant. In one embodiment the plant is selected from the group consisting of maize, wheat, rice, sorghum, oats, rye, bananas, sugar cane, soybean, cotton, sunflower, and canola, hi one embodiment the plant is Zea mays. In accordance with one embodiment the plant, plant tissue, or plant cell comprises SEQ ID NO: 1, SEQ ID NO: 15 or a sequence having 90. 95, 98 or 99% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 15 operably linked to a non-ubiquitin transgene. In one embodiment the plant, plant tissue, or plant cell comprises a promoter operably linked to a transgene wherein the promoter consists of SEQ ID NO: 1, SEQ ID NO: 15 or a sequence having 90. 95, 98 or 99% sequence identity with SEQ ID NO: 1 or SEQ ID NO: 15. In accordance with one embodiment the gene construct comprising non-endogenous ubiquitin derived promoter sequence operably linked to a transgene is incorporated into the genome of the plant, plant tissue, or plant cell.

In one embodiment a non-Brachypodium plant, plant tissue, or plant cell is provided comprising SEQ ID NO: 1, or a sequence that has 90, 95, 98 or 99% sequence identity with SEQ ID NO: 1, operably linked to a transgene. In accordance with one embodiment the non-Brachypodium plant, plant tissue, or plant cell is a dicotyledonous or monocotyledonous plant or plant cell or tissue derived from a dicotyledonous or monocotyledonous plant. In one embodiment the plant is selected from the group consisting of maize, wheat, rice, sorghum, oats, lye, bananas, sugar cane, soybean, cotton, sunflower, and canola. In one embodiment the plant is Zea mays, hi accordance with one embodiment the promoter sequence operably linked to a transgene is incorporated into the genome of the plant, plant tissue, or plant cell. In one embodiment the plant, plant tissue, or plant cell further comprises a 5' untranslated sequence comprising SEQ ID NO: 11 or a sequence that has 90% sequence identity with SEQ ID NO: 11, wherein the 5' untranslated sequence is inserted between, and operably linked to, said promoter and said transgene. In a further embodiment the plant, plant tissue, or plant cell further comprises an intron sequence inserted after the 5' untranslated sequence. In one embodiment the intron sequence is an intron sequence isolated from a ubiquitin gene of Panicum virgatum, Brachypodium distachyon, or Setaria italica. In one embodiment the sequence comprises or consists of SEQ ID NO: 7.

In one embodiment a non-Brachypodium plant, plant tissue, or plant cell is provided that comprises SEQ ID NO: 1, or a sequence that has 90. 95, 98 or 99% sequence identity with SEQ ID NO: 1, operably linked to the 5' end of a transgene and a 3' untranslated sequence comprising SEQ ID NO: 4 or a sequence that has 90% sequence identity with SEQ ID NO: 4, wherein the 3' untranslated sequence is operably linked to said transgene. In accordance with one embodiment the non-Brachypodium plant, plant tissue, or plant cell is a dicotyledonous or monocotyledonous plant or is a plant issue or cell derived from a dicotyledonous or monocotyledonous plant. In one embodiment the plant is selected from the group consisting of maize, wheat, rice, sorghum, oats, rye, bananas, sugar cane, soybean, cotton, sunflower, and canola. In one embodiment the plant is Zea mays. In accordance with one embodiment the promoter sequence operably linked to a transgene is incorporated into the genome of the plant, plant tissue, or plant cell. In one embodiment the plant, plant tissue, or plant cell further comprises a 5' untranslated sequence comprising SEQ ID NO: 11 or a sequence that has 90% sequence identity with SEQ ID NO: 11, wherein the 5' untranslated sequence is inserted between, and operably linked to, said promoter and said transgene. In a further embodiment the plant, plant tissue, or plant cell further comprises an intron sequence inserted after the 5' untranslated sequence. In one embodiment the intron sequence is an intron sequence isolated from a ubiquitin gene of Panicum virgatum, Brachypodium distachyon, or Setaria italica. In one embodiment the 5' untranslated sequence consists of SEQ ID NO: 11.

In one embodiment a non-Brachypodium plant, plant tissue, or plant cell is provided that comprises SEQ ID NO: 15, or a sequence having 90% sequence identity with SEQ ID NO: 15 operably linked to a transgene. In one embodiment a non-Brachypodium plant, plant tissue, or plant cell is provided that comprises a promoter operably linked to a transgene, wherein the promoter consists of SEQ ID NO: 15, or a sequence having 90% sequence identity with SEQ ID NO: 15. In a further embodiment non-Brachypodium plant, plant tissue, or plant cell further comprises a 3' untranslated sequence of a ubiquitin gene of Panicum virgatum, Brachypodium distachyon, or Setaria italica. In one embodiment the 3' untranslated sequence comprises or consists of SEQ ID NO: 4 or a sequence that has 90% sequence identity with SEQ ID NO: 4, wherein the 3' untranslated sequence is operably linked to 3' end of the transgene.

In an embodiment, a plant, plant tissue, or plant cell according to the methods disclosed herein can be a monocotyledonous plant. The monocotyledonous plant, plant tissue, or plant cell can be, but not limited to corn, rice, wheat, sugarcane, barley, rye, sorghum, orchids, bamboo, banana, cattails, lilies, oat, onion, millet, and triticale.

In an embodiment, a plant, plant tissue, or plant cell according to the methods disclosed herein can be a dicotyledonous plant. The dicotyledonous plant, plant tissue, or plant cell can be, but not limited to rapeseed, canola, indian mustard, ethiopian mustard, soybean, sunflower, and cotton.

With regard to the production of genetically modified plants, methods for the genetic engineering of plants are well known in the art. For instance, numerous methods for plant transformation have been developed, including biological and physical transformation protocols for dicotyledonous plants as well as monocotyledonous plants (e.g., Goto-Fumiyuki et αℓ., Nature Biotech 17:282-286 (1999); Miki et αℓ., Methods in Plant Molecular Biology and Biotechnology, Glick, Β. R. and Thompson, J. Ε. Eds., CRC Press, Inc., Boca Raton, ρρ. 67-88 (1993)). In addition, vectors and in vitro culture methods for plant cell or tissue transformation and regeneration of plants are available, for example, in Gruber et αℓ., Methods in Plant Molecular Biology and Biotechnology, Glick, Β. R. and Thompson, J. Ε. Eds., CRC Press, Inc., Boca Raton, ρρ. 89-119 (1993).

One of skill in the art will recognize that after the exogenous sequence is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

A transformed plant cell, callus, tissue or plant may be identified and isolated by selecting or screening the engineered plant material for traits encoded by the marker genes present on the transforming DNA. For instance, selection can be performed by growing the engineered plant material on media containing an inhibitory amount of the antibiotic or herbicide to which the transforming gene construct confers resistance. Further, transformed cells can also be identified by screening for the activities of any visible marker genes (e.g., the yfp, gfp, P-glucuronidase, luciferase, Β or Cl genes) that may be present on the recombinant nucleic acid constructs. Such selection and screening methodologies are well known to those skilled in the art.

Physical and biochemical methods also may be used to identify plant or plant cell transformants containing inserted gene constructs. These methods include but are not limited to: 1) Southern analysis or PCR amplification for detecting and determining the structure of the recombinant DNA insert; 2) Northern blot, SI RNase protection, primer-extension or reverse transcriptase-PCR amplification for detecting and examining RNA transcripts of the gene constructs; 3) enzymatic assays for detecting enzyme or ribozyme activity, where such gene products are encoded by the gene construct; 4) Next Generation Sequencing analysis; 5) protein gel electrophoresis, Western blot techniques, immunoprecipitation, or enzyme-linked immunoassays (ELISA), where the gene construct products are proteins. Additional techniques, such as in situ hybridization, enzyme staining, and immunostaining, also may be used to detect the presence or expression of the recombinant construct in specific plant organs and tissues. The methods for doing all these assays are well known to those skilled in the art.

Effects of gene manipulation using the methods disclosed herein can be observed by, for example, northern blots of the RNA (e.g., mRNA) isolated from the tissues of interest.

Typically, if the mRNA is present or the amount of mRNA has increased, it can be assumed that the corresponding transgene is being expressed. Other methods of measuring gene and/or encoded polypeptide activity can be used. Different types of enzymatic assays can be used, depending on the substrate used and the method of detecting the increase or decrease of a reaction product or by-product. In addition, the levels of polypeptide expressed can be measured immunochemically, i.e., ELISA, RIA, EIA and other antibody based assays well known to those of skill in the art, such as by electrophoretic detection assays (either with staining or western blotting). As one non-limiting example, the detection of the AAD-1 (aryloxyalkanoate dioxygenase; see WO 2005/107437) and PAT (phosphinothricin-N-acetyltransferase ), EC 2.3.1.183) proteins using an ELISA assay is described in U.S. Patent Publication No. 20090093366 which is herein incorporated by reference in its entirety. The transgene may be selectively expressed in some cell types or tissues of the plant or at some developmental stages, or the transgene may be expressed in substantially all plant tissues, substantially along its entire life cycle. However, any combinatorial expression mode is also applicable.

The present disclosure also encompasses seeds of the transgenic plants described above wherein the seed has the transgene or gene construct. The present disclosure further encompasses the progeny, clones, cell lines or cells of the transgenic plants described above wherein said progeny, clone, cell line or cell has the transgene or gene construct.

While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications and changes may be made without departing from the invention.

The binary expression vectors were transformed into Agrobacterium tumefaciens strain DAU3192 (RecA minus ternary strain) (Int’l. Pat. Pub. No. WO2012016222). Bacterial colonies were isolated, and binary plasmid DNA was isolated and confirmed via restriction enzyme digestion.

Agrobacterium Culture Initiation. Agrobacterium cultures were streaked from glycerol stocks onto Agrobacterium (ΑΒ) minimal medium (as disclosed in WO 2013090734, the disclosure of which is incorporated herein by reference) and incubated at 20°C in the dark for 3 days.

Agrobacterium cultures were then streaked onto a plate of YEP (see WO 2013090734) medium and incubated at 20°C in the dark for 1 day.

On the day of the experiment, a mixture of inoculation medium (see WO 2013090734) and acetosyringone were prepared in a volume appropriate to the number of bacterial strains comprising plant transformation constructs in the experiment. Inoculation medium was pipetted into a sterile, disposable 250 ml flask. Next, a 1 Μ stock solution of acetosyringone in 100% dimethyl sulfoxide was added to the flask containing inoculation medium in a volume appropriate to make a final acetosyringone concentration of 200 μΜ. The required volumes of Inoculation medium and 1 Μ acetosyringone stock solution are listed in TABLE 1.

For each construct, 1 -2 loops of Agrobacterium from the YEP plate were suspended in 15 ml of the inoculation medium/acetosyringone mixture inside a sterile, disposable 50 ml centrifuge tube, and the optical density of the solution at 600 nm (Οϋ℮οο) was measured in a spectrophotometer. The suspension was then diluted down to 0.25-0.35 Οϋ℮οο using additional inoculation medium/acetosyringone mixture. The tube of Agrobacterium

suspension was then placed horizontally on a platform shaker set at about 75 rpm at room

temperature and incubated between 1 and 4 hours before use.

Ear sterilization and embryo isolation. Ears from Zea mays cultivar Β104 were harvested 10-12 days post pollination. Harvested ears were de-husked and surface-sterilized by immersion in a 20% solution of commercial bleach (Ultra Clorox® Germicidal Bleach, 6.15% sodium hypochlorite) and two drops of Tween® 20, for 20 minutes, followed by three rinses in sterile, deionized water inside a laminar flow hood. Immature zygotic embryos (1.8-2.2 mm long) were aseptically excised from each ear and distributed into one or more microcentrifuge tubes containing 2.0 ml of Agrobacterium suspension into which 2 pi of 10% Break-Thru® S233 surfactant had been added.

Agrobacterium co-cultivation. Upon completion of the embryo isolation activity, the tube of embryos was closed and placed on a rocker platform for 5 minutes. The contents of the tube were then poured out onto a plate of co-cultivation medium, and the liquid Agrobacterium suspension was removed with a sterile, disposable transfer pipette. The co-cultivation plate containing embryos was placed at the back of the laminar flow hood with the lid ajar for 30 minutes; after which time the embryos were oriented with the scutellum facing up using a microscope. The co-cultivation plate with embryos was then returned to the back of the laminar flow hood with the lid ajar for a further 15 minutes. The plate was then closed, sealed with 3M® Micropore® tape, and placed in an incubator at 25°C with 24 hours/day light at approximately 60 pmol m"² s"¹ light intensity

Callus Selection and Regeneration of Transgenic Events. Following the co-cultivation period, embiyos were transferred to Resting medium (see WO 2013090734). No more than 36 embryos were moved to each plate. The plates were placed in clear boxes and incubated at 27°C with 24 hours/day light at approximately 50 pmol m"² s"¹ light intensity for 7-10 days. Callused embryos were then transferred onto Selection I medium (see WO 2013090734). No more than 18 callused embryos were moved to each plate of Selection 1. The plates were placed in clear boxes and incubated at 27 °C with 24 hours/day light at approximately 50 pmol m² s"¹ light intensity for 7 days. Callused embryos were then transferred to Selection II medium (see WO 2013090734). No more than 12 callused embryos were moved to each plate of Selection II media. The plates were placed in clear boxes and incubated at 27°C with 24 hours/day light at approximately 50 pmol m² s¹ light intensity for 14 days.

At this stage resistant calli were moved to Pre-Regeneration medium (see WO 2013090734). No more than 9 calli were moved to each plate of Pre-Regeneration media.

The plates were placed in clear boxes and incubated at 27 °C with 24 hours/day light at approximately 50 pmol m‘² s'¹ light intensity for 7 days. Regenerating calli were then transferred to Regeneration medium in Phytatrays™ (see WO 2013090734). and incubated at 28°C with 16 hours light/8 hours dark per day at approximately 150 pmol nf² s'¹ light intensity for 7-14 days or until shoots develop. No more than 5 calli were placed in each Phytatray™. Small shoots with primary roots were then isolated and transferred to Shoot Elongation medium (see WO 2013090734). Rooted plantlets about 6 cm or taller were transplanted into soil and moved out to a growth chamber for hardening off.

YFP Transient expression. Transient YFP expression was observed in transformed embryos and after 3 days of co-cultivation with Agrobacterium. The embryos were observed under a stereomicroscope (Leica Microsystems, Buffalo Grove, 1L) using a YFP filter and 500 nm light source.

Transfer and Establishment of To Plants in the Greenhouse. Transgenic plants were transferred on a regular basis to the greenhouse. Plants were transplanted from Phytatrays™ to small pots (Τ. O. Plastics, 3.5” SVD, 700022C) filled with growing media (Premier Tech Horticulture, ProMix ΒΧ, 0581 Ρ) and covered with humidomes to help acclimate the plants.

Plants were placed in a Conviron growth chamber (28 °C/24 °C, 16-hour photoperiod, 50-70% RH, 200 pmol m"² s"¹ light intensity) until reaching V3-V4 stage. This aided in acclimating the plants to soil and harsher temperatures. Plants were then moved to the greenhouse (Light Exposure Type: Photo or Assimilation; High Light Limit: 1200 pmol m“² s^-1 photosynthetically active radiation (PAR); 16-hour day length; 27 °C Day/24 °C Night) and transplanted from the small pots to 5.5 inch pots. Approximately 1-2 weeks after transplanting to larger pots plants were sampled for bioassay. One plant per event was assayed.

The maize ubiquitin coding sequence was BLASTx searched in the Phytozome (Goodstein et al., 2012) database using Brachypodium distachyon and Setaria italica as target genomes.

Maize Ubiquitin (ΖΜ Ubil) Coding Sequence ATGCAGATCTTTGTGAAAACCCTGACTGGCAAGACTATCACCCTCGAGGTGGAGTCGTCTGAC ACCATTGACAACGTTAAGGCCAAGATCCAGGACAAGGAGGGCATCCCCCCAGACCAGCAGCG GCTCATCTTTGCTGGCAAACAGCTTGAGGACGGGCGCACGCTTGCTGACTACAACATCCAGAA GACCGGCAAGACTATCACCCTCGAGGTGGAGTCCTCTGACACCATTGACAACGTCAAGGCCAA GATCCAGGACAAGGAGGGCATCCCTCCAGACCAGCAGCGGCTCATCTTTGCTGGGAAGCAGC TTGAGGACGGGCGCACGCTTGCCGACTACAACATCCAGAAGGAGAGCACCCTCCACTTGGTG CTGCGCCTCAGGGGAGGCATGCAGATCTTCGTGAAGACCCTGACCGGCAAGACTATCACCCTC GAGGTGGAGTCTTCAGACACCATCGACAACGTCAAGGCCAAGATCCAGGACAAGGAGGGCAT TCCCCCAGACCAGCAGCGGCTCATCTTTGCTGGAAAGCAGCTTGAGGACGGGCGCACGCTTGC CGACTACAACATCCAGAAGGAGAGCACCCTCCACTTGGTGCTGCGCCTCAGGGGAGGCATGC AGATCTTCGTGAAGACCCTGACCGGCAAGACTATCACCCTCGAGGTGGAGTCTTCAGACACCA TCGACAATGTCAAGGCCAAGATCCAGGACAAGGAGGGCATCCCACCGGACCAGCAGCGTTTG ATCTTCGCTGGCAAGCAGCTGGAGGATGGCCGCACCCTTGCGGATTACAACATCCAGAAGGA GAGCACCCTCCACCTGGTGCTCCGTCTCAGGGGTGGTATGCAGATCTTTGTGAAGACACTCAC TGGCAAGACAATCACCCTTGAGGTGGAGTCTTCGGATACCATTGACAATGTCAAGGCCAAGAT CCAGGACAAGGAGGGCATCCCACCCGACCAGCAGCGCCTCATCTTCGCCGGCAAGCAGCTGG AGGATGGCCGCACCCTGGCGGATTACAACATCCAGAAGGAGAGCACTCTCCACCTGGTGCTCC GCCTCAGGGGTGGCATGCAGATTTTTGTGAAGACATTGACTGGCAAGACCATCACCTTGGAG GTGGAGAGCTCTGACACCATTGACAATGTGAAGGCCAAGATCCAGGACAAGGAGGGCATTCC CCCAGACCAGCAGCGTCTGATCTTTGCGGGCAAGCAGCTGGAGGATGGCCGCACTCTCGCGG ACTACAACATCCAGAAGGAGAGCACCCTTCACCTTGTTCTCCGCCTCAGAGGTGGTATGCAGA TCTTTGTAAAGACCCTGACTGGAAAAACCATAACCCTGGAGGTTGAGAGCTCGGACACCATCG ACAATGTGAAGGCGAAGATCCAGGACAAGGAGGGCATCCCCCCGGACCAGCAGCGTCTGATC TTCGCCGGCAAACAGCTGGAGGATGGCCGCACCCTAGCAGACTACAACATCCAAAAGGAGAG CACCCTCCACCTTGTGCTCCGTCTCCGTGGTGGTCAGTAA (SEQ ID ΝΟ:18)

The protein alignments are shown in Figure 1. Two sequences that aligned with the Zea mays Ubiquitin 1 protein were identified from Brachypodium distachyon. Only one sequence that aligned with the Zea mays Ubiquitin 1 protein was identified each from Setaria italic and Panicum virgatum. An approximately 2 kb DNA sequence upstream from a predicted translational start site (ATG) was determined to be the beginning of the putative promoter sequence and used for expression characterization. The polynucleotide sequence alignments of the novel promoters that were isolated from Panicum virgatum, Brachypodium distachyon and Setaria italica were aligned to the ΖΜ Ubil promoter and found to share low levels of sequence similarity across the 2 kb DNA region (Figs. 2A-C).

The UBI coding sequence and putative promoter for the Panicum virgatum, Brachypodium distachyon and Setaria italica ubiquitin genes are indicated in Figs 35-38.

The four promoter sequences were commercially synthesized and incorporated into plasmid vectors as depicted in Fig. 3 (pDAB 113091), Fig. 4 (pDΑΒ113092), Fig. 5 (pDABl 13066) and Fig. 22 (pDABl 18238). Similarly four 3’UTR/transcription termination sequences were commercially synthesized and incorporated into plasmid vectors as depicted in Fig. 23 (pDABl 18237), Fig. 24 (pDABl 18207), Fig. 25 (pDAB 118208 ) and Fig. 26 (pDAB118209).. The sequences were flanked by 15-18 nucleotide homology fragments on both ends for seamless cloning (GeneArt® Seamless Cloning and Assembly Kit, Invitrogen, Carlsbad, CA) and type II restriction enzyme sites inserted for the isolation of promoter fragments. Seamless cloning compatible Ζ℮α mays Ubil promoter (Christensen and Quail (1996) Transgenic Research. 5; 213-218; Christensen et al., (1992) Plant Molecular Biology. 18; 675-689) or Oryzae sativa Actin promoter (McElroy et al., (1990) Plant Cell. 2; 163-71), and PhiYFP (Shagin et ah, (2004) Mol Biol Evol. 21; 841-50) coding sequence comprising the ST-LS1 intron (Vancanneyt et al., (1990) Mol Gen Genet. 220; 245-50), and St Pinll or native 3’-UTR (An et al., 1989 Plant Cell.

1; 115-22.) fragments were obtained using PCR or typell restriction enzymes. Finally, the promoter :: PhiYFP :: St Pinll 3’-UTR fragments were assembled using seamless cloning to create transient expression vectors (Fig. 6, pDABl 13103: Fig. 7, pDAB113104; Fig. 8, pDAB 113105;

Fig. 9, pDABl 13106; and, Fig. 10, ρϋΑΒ113107; Fig. 27, pDAB120403; Fig. 28, ρϋΑΒ118234, Fig. 29, pDABl 18235; and Fig. 30, pDABl 18236) for transient expression testing. These transient expression vectors were integrated into a binary vector containing the Zm Ubi 1 promoter and AAD-1 coding sequence (International Patent Publication No. 2005107437) and Zm Lip 3’UTR (Paek et αℓ., (1998) Molecules and Cells, 8(3): 336-342). The resulting binaries were confirmed via restriction enzyme digestion and sequencing reaction (Fig. 12, pDAB 113117; Fig.

13, pDAB 113118; Fig. 14, pDABl 13119; Fig. 15, pDABl 13120; Fig. 16, ρϋΑΒ113121; Fig. 31, pDAB 120400; Fig. 32, pDAB l 20404; Fig. 33, pDAB120401; and, Fig. 34, pDAB 120402).

Transient expression was tested using particle bombardment of immature maize (B104) embryos. Forty embryos were used per treatment in a Petri plate for bombardment. YFP image analysis was done after overnight incubation of particle bombardment. Figure 19 shows YFP expression levels obtained from the novel promoters. The data show that YFP expression levels obtained from the novel promoters (pDABl 13103, pDABl 13104, and pDAB l 13105) is comparable to the YFP expression levels obtained from the ZM Ubil promoter (pDABl 13106) and the OS Act 1 promoter (pDAB 113107) as visually observed under the microscope. Plant tissues were imaged on a Leica EL6000 - mercury metal halide™ microscope. Confocal and Differential Interference Contrast (DIC) images were captured using Chroma 42003- ZsYellow 1™ filters.

The stable integration of the yfp transgene within the genome of the transgenic Ζ. mays plants was confirmed via a hydrolysis probe assay. Stably-transformed transgenic Ζ. mays plantlets that developed from the callus were obtained and analyzed to identify events that contained a low copy number (1-2 copies) of full-length T-strand inserts. Identified plantlets were advanced to the green house and grown.

The Roche Light Cycler480™ system was used to determine the transgene copy number. The method utilized a biplex TaqMan¹’ reaction that employed oligonucleotides specific to the yfp gene and to the endogenous Ζ. mays reference gene, invertase (Genbank Accession No: U 16123.1), in a single assay. Copy number and zygosity were determined by measuring the intensity of y/p-specific fluorescence, relative to the invertase-specific fluorescence, as compared to known copy number standards.

A yfp gene-specific DNA fragment was amplified with one TaqMan ' primer/probe set containing a probe labeled with FAM™ fluorescent dye, and invertase was amplified with a second TaqMan® primer/probe set containing a probe labeled with HEX™ fluorescence (TABLE 2). The PCR reaction mixture was prepared as set forth in TABLE 3, and the gene-specific DNA fragments were amplified according to the conditions set forth in TABLE 4. Copy number and zygosity of the samples were determined by measuring the relative intensity of fluorescence specific for the reporter gene, yfp, to fluorescence specific for the reference gene, invertase, as compared to known copy number standards.

TABLE 3: Taqman® PCR reaction mixture.

Concentration Concentrati (μ1)

on

Water - - 0.5

Standards were created by diluting the vector, pDAB 108706, into Ζ. mays Β104 genomic DNA (gDNA) to obtain standards with a known relationship of pDAB108706:gDNA. For example, samples having one; two; and four cop(ies) of vector DNA per one copy of the Ζ. mays Β104 gDNA were prepared. One and two copy dilutions of the pDAB 108706 mixed with the Ζ. mays Β104 gDNA standard were validated against a control Ζ. mays event that was known to be hemizygous, and a control Ζ. mays event that was known to be homozygous (Ζ.

mays event 278; see PCT International Patent Publication No. WO 2011/022469 Α2). A TaqMan® biplex assay that utilizes oligonucleotides specific to the AAD1 gene and oligonucleotides specific to the endogenous Ζ. mays reference gene, invertase, was performed by amplifying and detecting a gene-specific DNA fragment for A ADI with one TaqMan® primer/probe set containing a probe labeled with FAM fluorescent dye, and by amplifying and detecting a gene-specific DNA fragment for invertase with a second TaqMan® primer/probe set containing a probe labeled with HEX™ fluorescence (TABLE 2). The AAD1 TaqMan® reaction mixture was prepared as set forth in TABLE 3, and the specific fragments were amplified according to the conditions set forth in TABLE 4,

The level of fluorescence that was generated for each reaction was analyzed using the Roche LightCycler® 480 Thermocycler according to the manufacturer’s directions. The FAM™ fluorescent moiety was excited at an optical density of 465/510 nm, and the HEX™ fluorescent moiety was excited at an optical density of 533/580 nm. The copy number was determined by comparison of Target/Reference values for unknown samples (output by the LightCycler® 480) to Target/Reference values of four known copy number standards (Null, 1-Copy (hemi), 2-Copy (homo) and 4-Copy). Results from the transgene copy number analysis of transgenic plants obtained via transformation with different promoter constructs are shown in TABLE 5. Only plants with 1-2 copies of the yfp transgene were transferred to the greenhouse for further expression analyses.

To plants were sampled at V4-5 using a leaf ELISA assays. Sample were collected in 96-well collection tube plate, and 4 leaf disks (paper hole punch size) were taken for each sample. Two 4.5mm BBs and 200 pL extraction buffer [lx PBS supplemented with 0.05% Tween®-20 and 0.05% BSA (Millipore Probumin®, EMD Millipore Corp.. Billerica, ΜΑ)] were added to each tube. For A ADI extraction, the concentration of BSA was increased to 0.5%. Plates were processed in a KLECO bead mill at full speed for 3 minutes. Additional 200 pL of extraction buffer was added to each tube followed by inversion to mix. Plates were spun for 5 minutes at 3000 rpm. Supernatant was transferred to corresponding wells in a deep well 96 stored on ice.

YFP and AAD1 ELISA Procedure

Nunc® 96-well Maxi-Sorp Plates (Thermo Fisher Scientific Inc., Rockford, IL ) were used for ELISA. Plates were coated with mouse monoclonal anti-YFP capture antibody (OriGene Technologies Inc., Rockville, MD). The antibody was diluted in PBS (1 pg/mL) and 150 pL of diluted PBS was added per well. The plates were incubated overnight at 4°C. The overnight plates were kept at room temperature for 20-30 minutes before washing 4χ with 350 pL of wash buffer [lx PBS supplemented with 0.05% Tween®-20 (Sigma-Aldrich, St. Louis, MO)]. Plates were blocked with 200 pL per well of blocking buffer [lx PBS supplemented with 0.05% Tween®-20 plus 0.5% BSA (Millipore Probumin®)] for a minimum of 1 hr at +37°C followed by 4χ washing with 350 pL of wash buffer (Tomtec QuadraWash™ 2, Tomtec, Inc., Hamden, CT).

For the YFP ELISA, Evrogen recombinant Phi-YFP lmg/mL (Axxora LLC, Farmingdale, NY) was used as a standard. A 5-parameter fit standard curve (between the 1 ng/ml and 0.125 ng/ml Standards) was used to ensure all data fall in the linear portion of the curve. 100 pL of standard or sample was added to the well. A minimum 1:4 dilution of sample in the Assay Buffer was used. Plates were incubated for lhr at RT on plate shaker (250 rpm;

Titer Plate shaker) followed by 4χ washing with 350 pL of wash buffer (Tomtec QuadraWash™ 2). About 100 pL of 1 pg/mL Evrogen rabbit polyclonal anti-PhiYFP primary antibody (Axxora) was added to each well. Plates were incubated for 1 hr at room temperature on a plate shaker at 250 rpm followed by 4χ washing with 350 pL of wash buffer (Tomtec QuadraWash™ 2). Next, 100 pL of anti-rabbit IgG HRP secondary antibody (Thermo Scientific) diluted 1:5000 in Blocking/Assay buffer, which was added to each well. Plates were incubated for 1 hr at room temperature on plate shaker at 250 rpm followed by 4χ washes with 350 pL of wash buffer (Tomtec QuadraWash™ 2). 100 pL of Pierce 1 Step Ultra ΤΜΒ ELISA (Thermo Scientific) substrate was added in the well with gentle shaking for 10 minutes. Reaction was stopped by adding 50 pL of 0.4Ν H2SO4. Absorbance was read at 450 nm with a 650 nm reference filter.

AAD1 expression levels were determined by ELISAs using kits from Acadia BioSciences (Portland, ME). The ELISAs were performed using multiple dilutions of the extracts and using the reagents and instructions provided by the supplier. The protein levels were normalized using total soluble protein assay, performed using the 660 nm protein assay reagent supplied by Thermo Scientific and following the supplier’s instructions.

Operably Linked to Ubiquitin Promoters

Whole plants that contained a low copy number of the binary plasmid were grown in a greenhouse. Plant tissues were imaged on a Leica EL6000 - mercury metal halide™ microscope. Confocal and Differential Interference Contrast (DIC) images were captured using Chroma 42003- ZsYellow 1™ filters. Representative examples of stable expression of YFP in callus and root tissue of transgenic T₀ maize plants obtained from Ζ. mays embryos transformed with the Brachypodium distachyon Ubiquitin 1 C, Brachypodium distachyon Ubiquitin 1, and Setaria italica ubiquitin 2 promoters described herein are presented in FIG. 20 to FIG. 21, respectively. The promoters drove robust expression of the yfp coding sequences both in callus (FIG. 20) and root (FIG. 21) plant tissues.

Additional data was produced from an ELISA analysis of the expressed YFP protein.

The ELISA analysis further confirmed that the novel promoters drove robust expression of a transgene. The quantitative measurements of YFP protein obtained from transgenic plants comprising novel promoter constructs are shown in FIG. 17 and TABLE 6. The data show that expression of YFP protein in the plants containing the novel promoters (pDABl 13117,

pDΑΒ113118, and pDAB 113119) is several fold higher that YFP expression obtained from the Os Actl (Rice Actinl) promoter (pDABl 13120). Comparatively, FIG. 18 and TABLE 7 show that similar level of AAD1 expression was obtained from all the constructs. This is expected because A ADI is driven by the Zm Ubil promoter for all of the constructs.

TABLE 6: Cross Species Ubiquitin Promoter To Leaf YFP expression

Construct Mean (ng/mg TSP) Statistical significance

pDAB113121 144.00173 A

TABLE 7: Cross Species Ubiquitin Promoter T₀ Leaf AAD1 expression

Levels not connected by same letter are significantly different

T₀ single transgene copy plants were backcrossed to wild type Β104 com plants to obtain Τΐ seed. Hemizygous Τΐ plants were used for analysis. Five events per construct and 5-10 plants per event for V4 and V12 leaf expression. Three events per construct and 3 plants per event were used for the other tissue type expression. Zygosity analysis was done for AAD1/YFP.

The quantitative measurements of YFP protein obtained from leaf tissue of Τΐ transgenic plants comprising novel promoter constructs are shown in TABLE 8. The data confirmed the T₀ leaf expression results and further showed that consistent high expression of YFP protein was obtained in the V4, V12 and R3 leaf tissue of the plants containing the novel promoters (pDABl 13117, pDABl 13118, and pDABl 13119). TABLE 8 also shows that there was several fold increase in the expression of YEP protein when this novel promoters were used in combination with their native 3’UTRs (pDAB120400, ρϋΑΒ120401, and

pDΑΒ120402) instead of PinD 3’UTR (pDAB 113117, pDAB 113118, and pDAB 113119).

YFP protein expression was detected from the plants containing construct pDAB 120404 confirming that novel promoter and 3’UTR used in this construct drive expression of a transgene.

:ϋ': : νΐ2^: : : Construct Event V4 Leaf Leaf R3 Leaf

High YFP protein expression was found in different tissue types including cob, husk, kernel, pollen, root, silk and stem sampled from the transgenic corn plants containing novel Ubiquitin Promoters driving YFP (Table 9). These data demonstrate that the novel promoters and 3’UTRs claimed here drive high constitutive expression of transgene in plants and would be useful for biotechnological applications.

Mean YFP (ng/mg TSP)

All references, including publications, patents, and patent applications, cited herein are

5 hereby incorporated by reference to the extent they are not inconsistent with the explicit details of this disclosure, and are so incorporated to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are

10 not entitled to antedate such disclosure by virtue of prior invention. The following examples are provided to illustrate certain particular features and/or embodiments. The examples should not be construed to limit the disclosure to the particular features or embodiments exemplified.